Salts of piperidine derivatives as inhibitors of nicotinamide n-methyl transferase
Crystalline orotate addition salts of piperidine derivatives provide effective NNMT inhibition, addressing the limitations of current treatments by stabilizing NNMT inhibitors and increasing NAD+ levels to halt kidney disease progression and improve heart function.
Patent Information
- Application Number
- PCT/EP2026/063265
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for chronic kidney disease and heart failure, such as inhibitors of the renin-angiotensin-aldosterone system and sodium/glucose cotransporter 2, fail to halt the progression of kidney function decline, and there is a need for stable, non-hygroscopic NNMT inhibitors to increase NAD+ levels and mitigate uremic toxins.
Development of pharmaceutically acceptable, crystalline orotate addition salts of piperidine derivatives that inhibit nicotinamide N-methyl transferase (NNMT), which are stable, crystalline, and have a high melting point, addressing the need for effective NNMT inhibitors.
The crystalline orotate addition salts effectively inhibit NNMT, potentially stopping the progression of kidney disease and improving cardiac function by increasing NAD+ levels, offering a therapeutic benefit for chronic kidney disease, acute kidney injury, diabetic kidney disease, heart failure, and other NNMT-related conditions.
Smart Images

Figure EP2026063265_12112026_PF_FP_ABST
Abstract
Description
[0001] SALTS OF PIPERIDINE DERIVATIVES AS INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE
[0002] TECHNICAL FIELD
[0003] The technical field relates to orotate crystalline addition salts of certain piperidine derivatives of Formula (I), to their use in the treatment of a nicotinamide N-m ethyl transferase related disease or condition, for example chronic kidney disease, acute kidney injury or heart failure.
[0004] BACKGROUND
[0005] Nicotinamide N-methyl transferase (NNMT) is a cytosolic methyl transferase expressed in many tissues with highest expression in liver, adipose tissue and blood vessels. In healthy kidney tissue, expression is very low but increases markedly in chronic kidney disease (CKD).
[0006] NNMT catalyzes the transfer of a methyl group from S -adenosyl L-m ethionine (SAM) to nicotinamide producing 1 -methyl nicotinamide (1-MNA) and S-adenosyl L-homocysteine (SAH) which can be further metabolized to homocysteine. Metabolism of nicotinamide to 1-MNA by NNMT and further to N-methyl-2-pyridone-5-carboxamide (N-Me-2Py) and N-methyl-4-pyridone-3-carboxamide (N-Me-4Py) via aldehyde oxidase leads to its excretion (Trends Endocrinol Metab., 2017, 28(5), 340-353). N-Me-2Py has been reported to be a uremic toxin (Toxins 2016, 8, 339). High NNMT-activity may affect cellular homeostasis of nicotinamide adenine dinucleotide (NAD+) by preventing nicotinamide from entering NAD+salvage pathway (Int J Mol Sci., 2023, 24, 137).
[0007] The heart and the kidneys are the most energy demanding organs in the body. Large amounts of ATP are required in kidney tubules to support solute transport. NAD+is required for the metabolism of glucose, pyruvate and fatty acids to acetyl-CoA and for metabolism of the latter in the Krebs cycle. The NADH generated in these processes is then used for ATP production in the electron transport chain. NAD+is also an important co-factor for the NAD+-dependent enzymes: sirtuins, PARPs and CD38 (Mol. Sci., 2023, 24, 137).Increase in cellular NNMT activity may also shift the ratio of SAM / SAH and thereby affect additional SAM-dependent methyl transferases, possibly leading to epigenetic changes. High NNMT activity will also lead to increased production of homocysteine (Atherosclerosis, 2009, 204(2), 412-7).
[0008] Transcriptomic analysis has demonstrated that NNMT is highly increased in human CKD of different etiologies including diabetic kidney disease (DKD) and highest NNMT expression in the tubulointerstitial compartment, particularly in proximal tubule cells (Int. J. Gen. Med, 2023, 3331-3344). Sci. Rep., 2022, 12, 6398) also report that NNMT localizes to atrophic tubular cells in fibrotic lesions in human CKD.
[0009] In serum from CKD patients, N-Me-2Py and N-Me-4Py increase and nicotinamide decrease with increasing CKD-stage (Sci. Rep., 2022, 12, 6398). Doke, T et al (Nat. Metab., 2023, Mar. 5, 414-430) report decreased nicotinamide and NAD+levels in kidney biopsies from CKD-patients.
[0010] Current standard of care for chronic kidney disease, that is, inhibitors of the renin-angiotensin-aldosterone system (RAAS) such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) and more recently, inhibitors of the sodium / glucose cotransporter 2 (SGLT2), slow down progression of CKD. Despite this treatment, many patients still continue to loose kidney function and progress towards end-stage kidney disease (ESKD) requiring kidneyreplacement therapy - dialysis or kidney transplantation (N. Engl. J. Med, 2020, 383, 1436; Cardiovasc Diabetol., 2021, 20, 36).
[0011] Pharmacological inhibition of NNMT activity could stop the progression of tubular and glomerular injury and thereby the decline in kidney function in different forms of CKD, including diabetic kidney disease, DKD (Int. J. Gen. Med., 2023, 16, 3331-3344).
[0012] Acute kidney injury (AKI) is associated with decreased kidney NAD+levels. Different approaches aimed at increasing kidney NAD+levels by supplementation with nicotinamide (NAM), nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) have shown protective effect in preclinical models of AKI (Clin Kidney J, 2021, 14(12), 2453-2462). Since inhibition of NNMT is expected to increase NAD+, NNMT -inhibitors may also be beneficial in AKI.In heart failure with preserved ejection fraction (HFpEF), cardiac levels of NAD+are decreased and in preclinical models of HFpEF, nicotinamide supplementation improved cardiac function, suggesting that NNMT -inhibition may also be beneficial in HFpEF (Set. Trans. Med., 2021, 13, 580).
[0013] Molecules 2021, 26, 991 disclose small molecule inhibitors of NNMT.
[0014] J. Med. Chem. 2022, 65 (21), 14642 disclose azaindole carboxamide inhibitors of NNMT.
[0015] WO2021163583 and WO2023129513 disclose NNMT inhibitors and methods of inhibiting tumor growth.
[0016] J. Med. Chem. 2019, 62 (21), 9837 disclose alkynyl inhibitors of NNMT.
[0017] WO2023129512 disclose NNMT inhibitors and methods of inhibiting tumor growth. Bioorg. Med. Chem. Lett. 2018, 28, 922 and WO2021025975 disclose nicotinamides that inhibits NNMT.
[0018] US 10,087,449 B2 discloses a therapeutic agent for treating chronic kidney disease comprising a substance which inhibits the enzymatic activity of NNMT.
[0019] WO2018183668 disclose quinoline derived small molecule inhibitors of NNMT. WO2012068463 discloses methods of inhibiting NNMT production or activity in a cell, and methods of treating or preventing obesity or a related metabolic condition, comprising administering a NNMT antagonist.
[0020] A need exists for inhibitors of NNMT in the form of a salt which is stable, crystalline, not hygroscopic and which has a relatively high melting point.
[0021] An object is to provide pharmaceutically acceptable crystalline orotate addition salts of compounds that are inhibitors of nicotinamide N-methyl transferase (NNMT), their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.
[0022] SUMMARY
[0023] There is provided an orotate crystalline addition salt of a compound of Formula (I)
[0024]
[0025] wherein
[0026] R1 is selected from a 8-, 9- or 10-membered heteroaryl substituted by R8, R10 and 0, 1 or 2 substituents independently selected from R9;
[0027] R2 is independently selected from H, CH3, CH2F, CHF2 and CF3;
[0028] R3is selected from a 5- or 6-membered heteroaryl substituted by R^®, 0, 1 or 2 substituents independently selected from RH, 0, 1 or 2 substituents independently selected from R12 and 0 or 1 substituents independently selected from R13 or a 8-, 9- or 10-membered heteroaryl substituted by R10, 0, 1 or 2 substituents independently selected from RH, 0, 1 or 2 substituents independently selected from R12 and 0 or 1 substituents independently selected from RIS;
[0029] R3is selected from H, OH, C|.3 alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl;
[0030] R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3;
[0031] R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0032] R3is selected from H, F, Cl, CN, C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu;
[0033] R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl;R9 is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -CH(CH3)2, CN, F or Cl;
[0034] R10 is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3; R11is independently selected from H, C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3;
[0035] R12 is independently selected from CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3 or CH2OH;
[0036] R13 is selected from a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3, or -O(6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N) wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3;
[0037] m is independently 0, 1 or 2.The compounds of Formula (I) are NNMT inhibitors. Thus, the compounds of Formula (I) may be used as a medicament, in particular for disorders, diseases or conditions responsive to inhibition of NNMT, and more specifically chronic kidney disease or kidney conditions or disorders in mammals including man. Further, the disclosed compounds are particularly indicated for use in the treatment of acute kidney injury (AKI), diabetic kidney disease (DKD), heart failure (HF), cardiorenal syndrome (CRS), metabolic dysfunction-associated steatohepatitis (MASH) and arrhythmia conditions or disorders in mammals including man.
[0038] Conditions or disorders that may be specifically mentioned include diabetic kidney disease, hypertensive nephropathy, rapidly progressive glomerulonephritis, systemic lupus erythematosus, IgA nephropathy, focal segmental glomerulosclerosis and acute kidney injury, coronary artery disease, acute coronary syndrome, heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction, in which NNMT plays a role.
[0039] BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 shows the X-ray powder diffraction pattern for Example 1, form A. Figure 2 shows the X-ray powder diffraction pattern for Example 2, form B. Figure 3 shows the X-ray powder diffraction pattern for Example 3.
[0041] Figure 4 shows the X-ray powder diffraction pattern for Example 4, Bragg-Bentano powder X-ray diffraction.
[0042] Figure 5 shows the X-ray powder diffraction pattern for Example 4, capillary transmission powder X-ray diffraction.
[0043] Figure 6 shows the X-ray powder diffraction pattern for Example 5.
[0044] Figure 7 shows the X-ray powder diffraction pattern for Example 6.
[0045] DETAILED DESCRIPTION
[0046] This detailed description and its specific examples, while indicating embodiments, are intended for purposes of illustration only. Therefore, there is no limitation to the illustrative embodiments described in this specification. In addition, it is to be appreciated that various features that are, for clarity reasons, described in the context of separate embodiments, also may be combined to form asingle embodiment. Conversely, various features that are, for brevity reasons, described in the context of a single embodiment, also may be combined to form subcombinations thereof.
[0047] Listed below are definitions of various terms used in the specification and claims.
[0048] It is to be understood that where in this specification a group is qualified by “defined above” said group encompasses the first occurring and broadest definition as well as each and all of the other definitions for that group.
[0049] It is to be understood that in this specification “€.3” means a carbon group having 1, 2 or 3 carbon atoms.
[0050] It is to be understood that in this specification “C^” means a carbon group having 1 or 2 carbon atoms.
[0051] It is to be understood that in this specification “cyPr” means cyclopropyl. It is to be understood that in this specification “cyBu” means cyclobutyl.
[0052] In this specification, unless stated otherwise, the term “alkyl” includes both straight and branched chain alkyl groups and may be, but is not limited to, methyl, ethyl, / / -propyl orz-propyl.
[0053] It is to be understood that in this specification “8-, 9- or 10-membered heteroaryl” means a bicyclic aromatic or partially aromatic ring with 8, 9 or 10 atoms and containing one or more heteroatoms independently selected from nitrogen, oxygen or sulphur.
[0054] It is to be understood that in this specification “5- or 6-membered heteroaryl” means an aromatic ring with 5 or 6 atoms and containing one or more heteroatoms independently selected from nitrogen, oxygen or sulphur.
[0055] It is to be understood that in this specification “6-membered heterocycloalkyl” means a partially or completely saturated ring system with 6 atoms and wherein at least one of the ring carbon atoms is replaced with a heteroatom independently selected from nitrogen, oxygen or sulphur.
[0056] It is to be understood that in this specification a “heterocycloalkyl” substituent may be attached via a nitrogen atom having the appropriate valences, or via any ring carbon atom.In this specification, unless stated otherwise, the term “pharmaceutically acceptable” is used to characterize a moiety (e.g. a salt, dosage form, or excipient) as being appropriate for use in accordance with sound medical judgment. In general, a pharmaceutically acceptable moiety has one or more benefits that outweigh any deleterious effect that the moiety may have. Deleterious effects may include, for example, excessive toxicity, irritation, allergic response, and other problems and complications.
[0057] In this specification, when it is stated that the present invention relates to a crystalline form of an orotate salt of a compound of Formula (I), the degree of crystallinity is conveniently greater than about 60%, more conveniently greater than about 80%, preferably greater than about 90% and more preferably greater than about 95%. Most preferably the degree of crystallinity is greater than about 98%.
[0058] In one embodiment, there are provided orotate crystalline addition salts of compounds of Formula (I), wherein R!-R13 and m are as defined in Formula (I).
[0059] In one embodiment R1 is selected from a 8-, 9- or 10-membered heteroaryl substituted by R^, R10 and 0, 1 or 2 substituents independently selected from R^.
[0060] R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl.
[0061] R9 is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH F, CHF2 or CF3, -CH(CH3)2, CN, F or Cl.
[0062] R10is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3.
[0063]
[0064]
[0065] R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl.
[0066] is independently selected from C|_2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC|_2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, cyBu substitutedby 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -CH(CH3)2, CN, F or Cl.
[0067] R10is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3.
[0068] n is 0, 1 or 2.
[0069] In still a further embodiment, R* is selected from
[0070]
[0071]
[0072]
[0073]
[0074] R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or Cl.
[0075] is independently selected from C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -CH(CH3)2, CN, F or Cl.
[0076] R10is selected from H, CH3, CH2F, CHF2, CF3 or CH2CH3.
[0077] n is 0, 1 or 2.In still a further embodiment, R* is selected from
[0078]
[0079]
[0080] R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl.
[0081] is independently selected from C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, - CH(CH3)2, CN, F or Cl.
[0082] n is 0, 1 or 2.In still a further embodiment, R* is selected from
[0083]
[0084]
[0085] R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3or Cl.
[0086] is independently selected from C|_2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC|_2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, - CH(CH3)2, CN, F or Cl.
[0087] n is 0, 1 or 2.
[0088]
[0089] In still a further embodiment, R* is selected from
[0090] R8is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl.
[0091] is independently selected from C|_2alkyl optionally substituted by 1, 2,
[0092]
[0093] ,, OC|_2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, - CH(CH3)2, CN, F or Cl.
[0094]
[0095] In still a further embodiment, R* is selected from
[0096] R8is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3or Cl.
[0097] is independently selected from C|_2alkyl optionally substituted by 1, 2,
[0098]
[0099] ,, OC|_2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, - CH(CH3)2, CN, F or Cl.n is 0, 1 or 2.
[0100] In one embodiment, R² is independently selected from H, CH3, CH2F, CHF2 and CF3.
[0101] In a further embodiment, R² is independently selected from H and CH3.
[0102] In still a further embodiment, R² is H.
[0103] In one embodiment, R³ is selected from a 5- or 6-membered heteroaryl substituted by R¹⁰, 0, 1 or 2 substituents independently selected from R¹¹, 0, 1 or 2 substituents independently selected from R¹² and 0 or 1 substituents independently selected from R¹³ or a 8-, 9- or 10-membered heteroaryl substituted by R¹⁰, 0, 1 or 2 substituents independently selected from R¹¹, 0, 1 or 2 substituents independently selected from R¹² and 0 or 1 substituents independently selected from R¹³
[0104] R10is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH₂F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3;
[0105] R11is independently selected from C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3;
[0106] R12 is independently selected from CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3 or CH2OH;
[0107] R13 is selected from a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3, or -O(6-membered heterocycloalkyl ringcontaining 1 or 2 heteroatoms independently selected from O, S or N) wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3.
[0108] In a further embodiment,
[0109]
[0110] is selected from
[0111]
[0112]
[0113] R10is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3.
[0114] R11 is independently selected from H, C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3.
[0115] R12 is independently selected from CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3 or CH2OH.
[0116] R13 is selected from H, a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3, or -O(6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N) wherein said6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3.
[0117] p is 0, 1 or 2.
[0118] q is 0, 1 or 2.
[0119] In still a further embodiment,
[0120]
[0121] is selected from
[0122]
[0123]
[0124] R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or Cl.
[0125] R10is selected from H, CH3, CH2F, CHF2, CF3 or CH2CH3.
[0126] Rll is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, CH2OCH3, cyPr, CH2cyPr or cyBu.
[0127] R12 is independently selected from OH, CH3, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3, CH2OH.
[0128]
[0129] p is 0, 1 or 2.
[0130] q is 0, 1 or 2.
[0131] In still a further embodiment, R3is selected from
[0132]
[0133] R10is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3.
[0134] R11is independently selected from C|_2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC|_2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3.
[0135] R12 is independently selected from CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3or CH2OH.
[0136] R13 is selected from H, a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3or (CO)CH3, or -O(6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N) wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3or (CO)CH3.
[0137] p is 0, 1 or 2.q is 0, 1 or 2.
[0138]
[0139] R10is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3.
[0140] R11is independently selected from C|_2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC|_2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3.
[0141] p is 0, 1 or 2.
[0142] bodiment, R3is selected from
[0143]
[0144] R10is selected from H, CH3, CH2F, CHF2, CF3or CH2CH3.
[0145] Rll is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, CH2OCH3, cyPr, CH2cyPr or cyBu.
[0146] p is 0, 1 or 2.
[0147] In one embodiment, R3is selected from H, OH, C|_3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^.3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl.
[0148] In a further embodiment, R3is selected from H, OH, OC|_3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, CN, F.
[0149] In still a further embodiment, R3is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F.
[0150] In still a further embodiment, R^ is OH.
[0151] In still a further embodiment, R^ is OCH3.In one embodiment, R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3.
[0152] In a further embodiment, R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3.
[0153] In still a further embodiment, R is independently selected from H, F, OH, OCH3 or CH3.
[0154] In still a further embodiment, R^ is independently selected from H, F or OH. In still a further embodiment, R is independently selected from H or OH.
[0155] In one embodiment, R^ is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3orF.
[0156] In a further embodiment, R^ is independently selected from H, CH3, CH2F, CHF2 or CF3.
[0157] In still a further embodiment, R^ is independently selected from H or CH3.
[0158] In one embodiment, R3is selected from H, F, Cl, CN, C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu.
[0159] In a further embodiment, R3is selected from H, F, Cl, CN or C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F.
[0160] In still a further embodiment, R3is selected from H, F, CH3 or CN.
[0161] In still a further embodiment, R² is H.
[0162] In one embodiment, R& is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl.
[0163] In a further embodiment, R3is selected from H, CH3, CH2F, CHF2, CF3, OCH3, OCH2F, OCHF2, OCF3 or Cl.
[0164] In still a further embodiment, R3is selected from H, CH3 or OCH3.
[0165] In still a further embodiment, R& is CH3.In one embodiment,
[0166]
[0167] is independently selected from H, C ^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, -CH(CH3)2, CN, F or Cl.
[0168] In a further embodiment,
[0169]
[0170] is independently selected from H, C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, CN, F or Cl.
[0171] In still a further embodiment, R^ is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, CN, F or Cl.
[0172] In still a further embodiment, R^ is independently selected from H, CH3, OCH3, CN, F or Cl.
[0173] In one embodiment, R^® is selected from H, CH3, CH2F, CHF2, CF3 or CH2CH3. In a further embodiment, R^® is selected from H or CH3.
[0174] In one embodiment, R11 is independently selected from H, C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3.
[0175] In a further embodiment, R11is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, CH2OCH3, cyPr, CH2cyPr or cyBu.
[0176] In still a further embodiment, R11is independently selected from H, CH3, CH2CH3, OCH3, CH2OCH3, cyPr, CH2cyPr or cyBu.
[0177] In still a further embodiment, R11is independently selected from H, CH3 or OCH3.In one embodiment, R!2 is independently selected from H, CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3 or CH2OH.
[0178] In a further embodiment, R!2 is independently selected from H, CH3, OCH3, CN, Cl or CH2OH.
[0179] In still a further embodiment, R!2 is independently selected from H, CH3, OCH3, CN or Cl.
[0180] In one embodiment, Rl^ is selected from H, a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3, or -O(6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N) wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents
[0181] 3,
[0182]
[0183] In one embodiment, m is 0, 1 or 2.
[0184] In a further embodiment, m is 0 or 1.
[0185] In still a further embodiment, m is 2.
[0186] In still a further embodiment, m is 1.
[0187] In still a further embodiment, m is 0.
[0188] In one embodiment, n is 0, 1 or 2.
[0189] In a further embodiment, n is 0 or 1.In still a further embodiment, n is 2.
[0190] In still a further embodiment, n is 1.
[0191] In still a further embodiment, n is 0.
[0192] In one embodiment, p is 0, 1 or 2.
[0193] In a further embodiment, p is 0 or 1.
[0194] In still a further embodiment, p is 2.
[0195] In still a further embodiment, p is 1.
[0196] In still a further embodiment, p is 0.
[0197] In one embodiment, q is 0, 1 or 2.
[0198] In a further embodiment, q is 0 or 1.
[0199] In still a further embodiment, q is 2.
[0200] In still a further embodiment, q is 1.
[0201] In still a further embodiment, q is 0.
[0202] In one embodiment, there are provided compounds of Formula (I) wherein R1 is selected from a 8-, 9- or 10-membered heteroaryl substituted by R8, R10 and 0, 1 or 2 substituents independently selected from R9;
[0203] R2 is independently selected from H, CH3, CH2F, CHF2 and CF3;
[0204] R3is selected from a 5- or 6-membered heteroaryl substituted by R10, 0, 1 or 2 substituents independently selected from RH, 0, 1 or 2 substituents independently selected from R12 and 0 or 1 substituents independently selected from R13 or a 8-, 9- or 10-membered heteroaryl substituted by R10, 0, 1 or 2 substituents independently selected from RH, 0, 1 or 2 substituents independently selected from R12 and 0 or 1 substituents independently selected from RIS;
[0205] R3is selected from OH, C|.3 alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^_ 3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl; R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3;R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0206] R is selected from H, F, Cl, CN, C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu;
[0207] R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl;
[0208] R9 is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -CH(CH3)2, CN, F or Cl;
[0209] R10 is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3; R11is independently selected from H, C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3;
[0210] R12 is independently selected from H, CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3 or CH2OH;
[0211] R13 is selected from H, a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3, or -O(6-membered heterocycloalkyl ringcontaining 1 or 2 heteroatoms independently selected from O, S or N) wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3;
[0212] m is independently 0, 1 or 2.
[0213] In a further embodiment, there are provided compounds of Formula (I) wherein
[0214]
[0215]
[0216] is independently selected from H, CH3, CH2F, CHF2 and CF3;
[0217]
[0218]
[0219] R4 is selected from OH, C1-3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl; R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3; R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F; R7 is selected from H, F, Cl, CN, C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu; R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl; R9 is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -CH(CH3)2, CN, F or Cl;R10 is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3; R11is independently selected from H, C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3;
[0220] R12 is independently selected from CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3 or CH2OH;
[0221] R13 is selected from H, a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3, or -O(6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N) wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3;
[0222] m is independently 0, 1 or 2;
[0223] n is 0, 1 or 2;
[0224] p is 0, 1 or 2;
[0225] q is 0, 1 or 2.
[0226] In a further embodiment, there are provided compounds of Formula (I) wherein
[0227]
[0228] is independently selected from H, CH3, CH2F, CHF2 and CF3;
[0229] R3 is selected from
[0230]
[0231] R4 is selected from OH, C1-3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl; R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3; R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F; R7 is selected from H, F, Cl, CN, C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu; R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl; R9 is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -CH(CH3)2, CN, F or Cl; R10 is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3; R11is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3;
[0232] R12 is independently selected from CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3 or CH2OH;R13is selected from a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3, or -O(6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N) wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3;
[0233] m is independently 0, 1 or 2;
[0234] n is 0, 1 or 2;
[0235] p is 0, 1 or 2;
[0236] q is 0, 1 or 2.
[0237] In still a further embodiment, there are provided compounds of Formula (I) wherein
[0238]
[0239] is independently selected from H, CH3, CH2F, CHF2 and CF3;
[0240] R3 is selected from
[0241]
[0242] R4 is selected from OH, C1-3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl; R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3; R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F; R7 is selected from H, F, Cl, CN, C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu; R8is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3or Cl; R9 is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted
[0243]
[0244] m is independently 0, 1 or 2;
[0245] n is 0, 1 or 2;
[0246] p is 0, 1 or 2;
[0247] q is 0, 1 or 2.
[0248] In still a further embodiment, there are provided compounds of Formula (I) wherein
[0249]
[0250]
[0251]
[0252] lected from H, CH3, CH2F, CHF2 and CF3;
[0253] R3 is selected from
[0254]
[0255] R4 is selected from OH, C|.3 alky I optionally substituted by 1, 2, 3, 4 or 5 F, OC3.
[0256] 3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl;
[0257] R is independently selected from F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3;
[0258] R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0259] R7is selected from H, F, Cl, CN, C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu;
[0260] R8is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3or Cl;
[0261] R9is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3, -CH(CH3)2, CN, F or Cl;
[0262] R10is selected from H, CH3, CH2F, CHF2, CF3 or CH2CH3;
[0263] R11is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, CH2OCH3, cyPr, CH2cyPr or cyBu;R12is independently selected from OH, CH3, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3, CH2OH;
[0264]
[0265] m is independently 0, 1 or 2;
[0266] n is 0, 1 or 2;
[0267] p is 0, 1 or 2;
[0268] q is 0, 1 or 2.
[0269] In still a further embodiment, there are provided compounds of Formula (I) wherein
[0270]
[0271] R2is H;
[0272] R3 is selected from
[0273]
[0274] R3is selected from OH, C1-3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-
[0275] 3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl;
[0276] R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3;
[0277] R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0278] R7is selected from H, F, CH3or CN;
[0279] R8is independently selected from H, CH3or OCH3;
[0280] R9is independently selected from CH3, OCH3, CN, F or Cl;
[0281] R10is selected from H or CH3;
[0282] R11is independently selected from CH3 or OCH3;
[0283] R12is independently selected from CH3, OCH3, CN or Cl;
[0284]
[0285] m is independently 0, 1 or 2;
[0286] n is 0, 1 or 2;
[0287] p is 0, 1 or 2;
[0288] q is 0, 1 or 2.
[0289] In still a further embodiment, there are provided compounds of Formula (I) wherein
[0290]
[0291] R1 is selected fromR2is H;
[0292]
[0293]
[0294] H, C|.3 alky I optionally substituted by 1, 2, 3, 4 or 5 F, OCj.
[0295] 3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl;
[0296] R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3;
[0297] R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0298] R7is selected from H, F, CH3or CN;
[0299] R8 is selected from H, CH3 or OCH3;
[0300] R9is independently selected from CH3, OCH3, CN, F or Cl;
[0301] R10is selected from H or CH3;
[0302] R11is independently selected from CH3 or OCH3;
[0303] R12is independently selected from CH3, OCH3, CN or Cl;
[0304]
[0305] m is independently 0, 1 or 2;
[0306] n is 0, 1 or 2;
[0307] p is 0, 1 or 2;
[0308] q is 0, 1 or 2.
[0309] In still a further embodiment, there are provided compounds of Formula (I) wherein
[0310]
[0311] R3 is selected from
[0312] R3is selected from OH, C1-3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-
[0313] 3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl;R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3;
[0314] R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0315] R7is selected from H, F, CH3or CN;
[0316] R8is independently selected from H, CH3or OCH3;
[0317] R9is independently selected from CH3, OCH3, CN, F or Cl;
[0318] R10is selected from H or CH3;
[0319] R11is independently selected from CH3 or OCH3;
[0320] m is independently 0, 1 or 2;
[0321] n is 0, 1 or 2;
[0322] p is 0, 1 or 2.
[0323] In still a further embodiment, there are provided compounds of Formula (I) wherein
[0324]
[0325] R1 is selected from
[0326] R2is H;
[0327] R3 is selected from
[0328]
[0329] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;
[0330] R5is independently selected from H, F or OH;
[0331] R6is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0332] R7is selected from H, F, CH3or CN;
[0333] R8 is selected from H, CH3 or OCH3;
[0334] R9is independently selected from CH3, OCH3, CN, F or Cl;
[0335] R10is selected from H or CH3;
[0336] R11is independently selected from CH3 or OCH3;
[0337] R12is independently selected from CH3, OCH3, CN or Cl;
[0338]
[0339] m is independently 0, 1 or 2;
[0340] n is 0, 1 or 2;
[0341] p is 0, 1 or 2;
[0342] q is 0, 1 or 2.
[0343] In still a further embodiment, there are provided compounds of Formula (I) wherein
[0344]
[0345] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;
[0346] R5is independently selected from H, F or OH;
[0347] R6is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0348] R7is selected from H, F, CH3or CN;
[0349] R8is independently selected from H, CH3or OCH3;
[0350] R9is independently selected from CH3, OCH3, CN, F or Cl;R10is selected from H or CH3;
[0351] R11is independently selected from CH3 or OCH3;
[0352] m is independently 0, 1 or 2;
[0353] n is 0, 1 or 2;
[0354] p is 0, 1 or 2.
[0355] In still a further embodiment, there are provided compounds of Formula (I) wherein
[0356]
[0357] R1 is selected from
[0358] R2is H;
[0359]
[0360] R3is selected from
[0361] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;
[0362] R5is independently selected from H, F or OH;
[0363] R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0364] R7is selected from H, F, CH3or CN;
[0365] R8 is selected from H, CH3 or OCH3;
[0366] R9is independently selected from CH3, OCH3, CN, F or Cl;
[0367] R10is selected from H or CH3;
[0368] R11is independently selected from CH3 or OCH3;
[0369] m is independently 0, 1 or 2;
[0370] n is 0, 1 or 2;
[0371] p is 0, 1 or 2.
[0372] In one embodiment, there are provided compounds of Formula (IA)
[0373]
[0374] wherein
[0375] R1 is selected from a 8-, 9- or 10-membered heteroaryl substituted by R8, R10 and 0, 1 or 2 substituents independently selected from R9;
[0376] R2 is independently selected from H, CH3, CH2F, CHF2 and CF3;
[0377] R3is selected from a 5- or 6-membered heteroaryl substituted by R4®, 0, 1 or 2 substituents independently selected from R44, 0, 1 or 2 substituents independently selected from R4^ and 0 or 1 substituents independently selected from R4^ or a 8-, 9- or 10-membered heteroaryl substituted by R40, 0, 1 or 2 substituents independently selected from R44, 0, 1 or 2 substituents independently selected from R12 and 0 or 1 substituents independently selected from R4^;
[0378] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;
[0379] R is selected from F or OH;
[0380] R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0381] R3is selected from H, F, Cl, CN, C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu;
[0382] R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl;
[0383] R9 is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -CH(CH3)2, CN, F or Cl;
[0384] R10 is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3; R11is independently selected from H, C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3;
[0385] R12 is independently selected from H, CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3 or CH2OH;
[0386] R13 is selected from H, a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3, or -O(6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N) wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3;
[0387] m is independently 0, 1 or 2.
[0388] In a further embodiment, there are provided compounds of Formula (IA) wherein R1 is selected from
[0389]
[0390]
[0391]
[0392] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;
[0393] R is selected from F or OH;
[0394] R6is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0395] R3is selected from H, F, Cl, CN, C] _2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC| _2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu;R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl;
[0396] R9 is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -CH(CH3)2, CN, F or Cl;
[0397] R10 is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3; R11is independently selected from H, C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3;
[0398] R12 is independently selected from CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3 or CH2OH;
[0399] R13 is selected from H, a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3, or -O(6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N) wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3;
[0400] m is independently 0, 1 or 2;n is 0, 1 or 2;
[0401] p is 0, 1 or 2;
[0402] q is 0, 1 or 2.
[0403] In a further embodiment, there are provided compounds of Formula (IA) wherein
[0404]
[0405]
[0406]
[0407] lected from H, CH3, CH2F, CHF2 and CF3;
[0408] selected from
[0409]
[0410] R9 is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -CH(CH3)2, CN, F or Cl;
[0411] R10 is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2or CF3;
[0412] R11 is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr,cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3;
[0413] R12 is independently selected from CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3 or CH2OH;
[0414] R13is selected from a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3, or -O(6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N) wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3;
[0415] m is independently 0, 1 or 2;
[0416] n is 0, 1 or 2;
[0417] p is 0, 1 or 2;
[0418] q is 0, 1 or 2.
[0419] In still a further embodiment, there are provided compounds of Formula (IA) wherein
[0420]
[0421] is independently selected from H, CH3, CH2F, CHF2 and CF3;
[0422] R3 is selected from
[0423]
[0424] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;R is selected from F or OH;
[0425] R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0426] R3is selected from H, F, Cl, CN, C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu;
[0427] R8is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3or Cl;
[0428] R^ is independently selected from C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or
[0429]
[0430] m is independently 0, 1 or 2;
[0431] n is 0, 1 or 2;
[0432] p is 0, 1 or 2;
[0433] q is 0, 1 or 2.In still a further embodiment, there are provided compounds of Formula (IA) wherein
[0434]
[0435] is independently selected from H, CH3, CH2F, CHF2 and CF3;
[0436]
[0437] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;
[0438] R is selected from F or OH;
[0439] R6is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0440] R3is selected from H, F, Cl, CN, C] _2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC| _2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu;
[0441] R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or Cl;
[0442] R^ is independently selected from C^.2alkyl optionally substituted by 1, 2, 3, 4 or
[0443]
[0444] m is independently 0, 1 or 2;
[0445] n is 0, 1 or 2;p is 0, 1 or 2;
[0446] q is 0, 1 or 2.
[0447] In still a further embodiment, there are provided compounds of Formula (IA) wherein
[0448]
[0449]
[0450] ,,,, R7is selected from H, F, CH3or CN;
[0451] R8is independently selected from H, CH3or OCH3;
[0452] R9is independently selected from CH3, OCH3, CN, F or Cl;
[0453] R10is selected from H or CH3;
[0454] R11is independently selected from CH3 or OCH3;
[0455] R12is independently selected from CH3, OCH3, CN or Cl;
[0456]
[0457] m is independently 0, 1 or 2;
[0458] n is 0, 1 or 2;
[0459] p is 0, 1 or 2;
[0460] q is 0, 1 or 2.In still a further embodiment, there are provided compounds of Formula (IA) wherein
[0461]
[0462] R1 is selected from
[0463] R2is H;
[0464] R3 is selected from
[0465]
[0466] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;
[0467] R is selected from F or OH;
[0468] R6 is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3 or F;
[0469] R7is selected from H, F, CH3or CN;
[0470] R8 is selected from H, CH3 or OCH3;
[0471] R9is independently selected from CH3, OCH3, CN, F or Cl;
[0472] R10is selected from H or CH3;
[0473] R11is independently selected from CH3 or OCH3;
[0474] R12is independently selected from CH3, OCH3, CN or Cl;
[0475]
[0476] m is independently 0, 1 or 2;
[0477] n is 0, 1 or 2;
[0478] p is 0, 1 or 2;
[0479] q is 0, 1 or 2.
[0480] In still a further embodiment, there are provided compounds of Formula (IA) wherein
[0481]
[0482] R2is H;
[0483]
[0484] R3is selected from
[0485] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;
[0486] R is selected from F or OH;
[0487] R6is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0488] R7is selected from H, F, CH3or CN;
[0489] R8is independently selected from H, CH3or OCH3;
[0490] R9is independently selected from CH3, OCH3, CN, F or Cl;
[0491] R10is selected from H or CH3;
[0492] R11is independently selected from CH3 or OCH3;
[0493] m is independently 0, 1 or 2;
[0494] n is 0, 1 or 2;
[0495] p is 0, 1 or 2.
[0496] In still a further embodiment, there are provided compounds of Formula (IA)
[0497]
[0498] R1 is selected from
[0499] R2is H;
[0500] R3is selected from
[0501]
[0502] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;
[0503] R is selected from F or OH;
[0504] R6is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0505] R7is selected from H, F, CH3or CN;
[0506] R8 is selected from H, CH3 or OCH3;
[0507] R9is independently selected from CH3, OCH3, CN, F or Cl;
[0508] R10is selected from H or CH3;
[0509] R11is independently selected from CH3 or OCH3;
[0510] R12is independently selected from CH3, OCH3, CN or Cl;
[0511]
[0512] m is independently 0, 1 or 2;
[0513] n is 0, 1 or 2;
[0514] p is 0, 1 or 2;
[0515] q is 0, 1 or 2.In still a further embodiment, there are provided compounds of Formula (IA) wherein
[0516]
[0517] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;
[0518] R is selected from F or OH;
[0519] R6 is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0520] R is selected from H, F, CH3 or CN;
[0521] R8is independently selected from H, CH3or OCH3;is independently selected from CH3, OCH3, CN, F or Cl;
[0522] R10is selected from H or CH3;
[0523] R11is independently selected from CH3 or OCH3;
[0524] m is independently 0, 1 or 2;
[0525] n is 0, 1 or 2;
[0526] p is 0, 1 or 2.
[0527] In still a further embodiment, there are provided compounds of Formula (IA) wherein
[0528]
[0529] R3is selected from
[0530] R4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F;
[0531] R is selected from F or OH;
[0532] R6is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;
[0533] R7is selected from H, F, CH3or CN;
[0534] R8 is selected from H, CH3 or OCH3;
[0535] R9is independently selected from CH3, OCH3, CN, F or Cl;
[0536] R10is selected from H or CH3;
[0537] R11is independently selected from CH3 or OCH3;
[0538] m is independently 0, 1 or 2;n is 0, 1 or 2;
[0539] p is 0, 1 or 2.
[0540] In one embodiment the orotate crystalline addition salt of a compound of Formula (I) is selected from:
[0541] 2-((4-(5'-Methoxy-1'-methyl-1'H,2H-[3,4'-bipyrazol]-5-yl)piperidin-l-yl)methyl)-4,7-dimethylpyrido[2,3-J]pyrimidine orotate,
[0542] 2-((4-(1',5'-Dimethyl-1'H,2H-[3,4'-bipyrazol]-5-yl)-4-methoxypiperidin-l-yl)methyl)-4-methylquinazoline orotate,
[0543] (37?,4S)-4-Methoxy-l-((4-methylquinazolin-2-yl)methyl)-4-(l',3',5'-trimethyl-17 / ,2J / -[3,4'-bipyrazol]-5-yl)piperidin-3-ol orotate,
[0544] 4-Methyl-2-((4-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)piperidin-l-yl)methyl)quinazoline orotate,
[0545] 4-Methyl-2-((4-(l',3',5'-trirnethyl-17 / ,2J / -[3,4'-bipyrazol]-5-yl)piperidin-l-yl)methyl)quinazoline orotate.
[0546] MEDICAL AND PHARMACEUTICAL USE
[0547] The compounds of Formula (I) are useful because they possess pharmacological activity as inhibitors of the enzyme NNMT.
[0548] The compounds of Formula (I) are indicated for use in the treatment or prophylaxis of diseases or conditions in which modulation of the activity of the enzyme nicotinamide N-methyl transferase (NNMT) is desirable. In particular, linkage of NNMT activity to disease has been implicated in chronic kidney disease. Therefore, the disclosed compounds are particularly indicated for use in the treatment of chronic kidney disease or kidney conditions or disorders in mammals including man. Further, the disclosed compounds are particularly indicated for use in the treatment of acute kidney injury (AKI), diabetic kidney disease (DKD), heart failure (HF), cardiorenal syndrome (CRS), metabolic dysfunction-associated steatohepatitis (MASH) and arrhythmia conditions or disorders in mammals including man.
[0549] Conditions or disorders that may be specifically mentioned include diabetic kidney disease, hypertensive nephropathy, rapidly progressive glomerulonephritis, systemic lupus erythematosus, IgA nephropathy, focal segmentalglomerulosclerosis and acute kidney injury, coronary artery disease, acute coronary syndrome, heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction.
[0550] Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening or identified through specific biomarker pattern to be particularly susceptible to developing the disease or condition.
[0551] For the above-mentioned therapeutic indications, the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired.
[0552] The orotate crystalline addition salts of compounds of Formula (I) may be used on their own, or in the form of appropriate pharmaceutical compositions in which the compound is in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Thus, another aspect concerns a pharmaceutical composition comprising an orotate crystalline addition salt of a compound of Formula (I) in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Administration may be by, but is not limited to, enteral (including oral, sublingual or rectal), intranasal, inhalation, intravenous, topical or other parenteral routes. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, Pharmaceuticals - The Science of Dosage Form Designs, M. E. Aulton, Churchill Livingstone, 2nd Ed. 2002. The pharmaceutical composition preferably comprises less than 80% and more preferably less than 50% of an orotate crystalline addition salt of a compound of Formula (I).
[0553] In one embodiment there is provided an orotate crystalline addition salt of a compound of Formula (I) for use in therapy, especially in the prevention or treatment of chronic kidney disease or kidney conditions or disorders in a mammal, particularly a human.In a further embodiment there is provided an orotate crystalline addition salt of a compound of Formula (I) for use in therapy, especially in the prevention or treatment of a condition where inhibition of NNMT would be beneficial.
[0554] In still a further embodiment there is provided an orotate crystalline addition salt of a compound of Formula (I) for use in therapy, especially in the prevention or treatment of chronic kidney disease in a mammal, particularly a human.
[0555] In still a further embodiment there is provided an orotate crystalline addition salt of a compound of Formula (I) for use in therapy, especially in the prevention or treatment of acute kidney injury in a mammal, particularly a human.
[0556] In still a further embodiment there is provided an orotate crystalline addition salt of a compound of Formula (I) for use in therapy, especially in the prevention or treatment of diabetic kidney disease in a mammal, particularly a human.
[0557] In still a further embodiment there is provided an orotate crystalline addition salt of a compound of Formula (I) for use in therapy, especially in the prevention or treatment of cardiorenal syndrome in a mammal, particularly a human.
[0558] In still a further embodiment there is provided an orotate crystalline addition salt of a compound of Formula (I) use in therapy, especially in the prevention or treatment of heart failure in a mammal, particularly a human.
[0559] In still a further embodiment there is provided an orotate crystalline addition salt of a compound of Formula (I) use in therapy, especially in the prevention or treatment of heart failure with reduced ejection fraction in a mammal, particularly a human. In still a further embodiment there is provided an orotate crystalline addition salt of a compound of Formula (I) for use in therapy, especially in the prevention or treatment of heart failure with preserved ejection fraction in a mammal, particularly a human.
[0560] In still a further embodiment there is provided an orotate crystalline addition salt of a compound of Formula (I) for use in therapy, especially in the prevention or treatment of MASH in a mammal, particularly a human.
[0561] In still a further embodiment there is provided an orotate crystalline addition salt of a compound of Formula (I) for use in therapy, especially in the prevention or treatment of arrhythmia in a mammal, particularly a human.In one embodiment there is provided a method of treating, or reducing the risk of, diseases or conditions in which inhibition of the enzyme NNMT is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I).
[0562] In a further embodiment there is provided a method of treating, or reducing the risk of, chronic kidney disease or kidney conditions or disorders, in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I).
[0563] In still a further embodiment there is provided a method of treating, or reducing the risk of, chronic kidney disease, in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I).
[0564] In still a further embodiment there is provided a method of treating, or reducing the risk of, acute kidney injury, in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I).
[0565] In still a further embodiment there is provided a method of treating, or reducing the risk of, diabetic kidney disease, in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I).
[0566] In still a further embodiment there is provided a method of treating, or reducing the risk of, cardiorenal syndrome, in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I).
[0567] In still a further embodiment there is provided a method of treating, or reducing the risk of, heart failure, in a person suffering from or at risk of, said disease orcondition, wherein the method comprises administering to the person a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I).
[0568] In still a further embodiment there is provided a method of treating, or reducing the risk of, heart failure with reduced ejection fraction, in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I).
[0569] In still a further embodiment there is provided a method of treating, or reducing the risk of, heart failure with preserved ejection fraction, in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I).
[0570] In still a further embodiment there is provided a method of treating, or reducing the risk of, MASH, in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I)
[0571] In still a further embodiment there is provided a method of treating, or reducing the risk of, arrhythmia, in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I)
[0572] In one embodiment there is provided a pharmaceutical formulation comprising a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I) and a pharmaceutically acceptable diluent, excipient and / or inert carrier.
[0573] In a further embodiment there is provided a pharmaceutical formulation comprising an orotate crystalline addition salt of a compound of Formula (I) in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in therapy, especially in the prevention or treatment of a condition where inhibition of NNMT would be beneficial.In still a further embodiment there is provided a pharmaceutical formulation comprising an orotate crystalline addition salt of a compound of Formula (I) in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in therapy, especially in the prevention or treatment of chronic kidney disease in a mammal, particularly a human.
[0574] In still a further embodiment there is provided a pharmaceutical formulation comprising an orotate crystalline addition salt of a compound of Formula (I) in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in therapy, especially in the prevention or treatment of acute kidney injury in a mammal, particularly a human.
[0575] In still a further embodiment there is provided a pharmaceutical formulation comprising a compound of Formula (I) in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in therapy, especially in the prevention or treatment of diabetic kidney disease in a mammal, particularly a human.
[0576] In still a further embodiment there is provided a pharmaceutical formulation comprising an orotate crystalline addition salt of a compound of Formula (I) in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in therapy, especially in the prevention or treatment of heart failure in a mammal, particularly a human.
[0577] In still a further embodiment there is provided a pharmaceutical formulation comprising an orotate crystalline addition salt of a compound of Formula (I) in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in therapy, especially in the prevention or treatment of heart failure with reduced ejection fraction in a mammal, particularly a human.
[0578] In still a further embodiment there is provided a pharmaceutical formulation comprising an orotate crystalline addition salt of a compound of Formula (I) in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in therapy, especially in the prevention or treatment of heart failure with preserved ejection fraction in a mammal, particularly a human.
[0579] In still a further embodiment there is provided a pharmaceutical formulation comprising an orotate crystalline addition salt of a compound of Formula (I) inadmixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in therapy, especially in the prevention or treatment of MASH in a mammal, particularly a human.
[0580] In still a further embodiment there is provided a pharmaceutical formulation comprising an orotate crystalline addition salt of a compound of Formula (I) in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in therapy, especially in the prevention or treatment of arrhythmia in a mammal, particularly a human.
[0581] There is also provided a process for the preparation of such a pharmaceutical composition which comprises mixing the ingredients.
[0582] The orotate crystalline addition salts of compounds of Formula (I) herein exemplified, when tested in an NNMT cellular assay, for example Test A described below, preferably with an IC50less than 50 μM. The orotate crystalline addition salts of compounds of Formula (I) also display promising pharmacological profiles by separating desired and undesired effects in vivo.
[0583] These and other embodiments are described in greater detail herein below, where further aspects will be apparent to one skilled in the art from reading this specification.
[0584] PHARMACOLOGICAL PROPERTIES
[0585] The orotate crystalline addition salts of compounds of Formula (I) or pharmaceutically acceptable salts thereof are believed to be useful in the prevention or treatment of chronic kidney disease or kidney conditions or disorders, acute kidney injury, heart failure, heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction, cardiorenal syndrome, metabolic dysfunction-associated steatohepatitis and arrhythmia conditions or disorders in a mammal, particularly a human.
[0586] For the avoidance of doubt, as used herein, the term “treatment” includes therapeutic and / or prophylactic treatment.
[0587] When a compound or salt described herein is administered as therapy for treating a disorder, a “therapeutically effective amount” is an amount sufficient to reduce orcompletely alleviate symptoms or other detrimental effects of the disorder, cure the disorder, reverse, completely stop, or slow the progress of the disorder or reduce the risk of the disorder getting worse.
[0588] The compounds described herein are thus indicated both in the therapeutic and / or prophylactic treatment of these conditions.
[0589] The compounds described herein have the advantage that they may be more efficacious, be less toxic, be more selective, be more potent, produce fewer side effects, be more easily absorbed, and / or have a better pharmacokinetic profile (e.g. higher oral bioavailability and / or lower clearance), than compounds known in the prior art.
[0590] COMBINATION THERAPY
[0591] The orotate crystalline addition salts of compounds of Formula (I) may also be administered in conjunction with other compounds used for the treatment of the above conditions.
[0592] In another embodiment, there is a combination therapy wherein an orotate crystalline addition salt of a compound of Formula (I) and a second active ingredient are administered concurrently, sequentially or in admixture, for the treatment of one or more of the conditions listed above. Such a combination may be used in combination with one or more further active ingredients.
[0593] Compounds described herein may be of use in treating cardiovascular, metabolic and renal disease in combination with agents that are angiotensin converting enzyme inhibitors, angiotensin receptor blockers, sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, glucagon-like peptide-1 modulators or endothelin receptor antagonists.
[0594] When used in a combination therapy, it is contemplated that the orotate crystalline addition salts of compounds of Formula (I) and the other active ingredients may be administered in a single composition, completely separate compositions, or a combination thereof. It also is contemplated that the active ingredients may be administered concurrently, simultaneously, sequentially, or separately. The particular composition(s) and dosing frequency(ies) of the combination therapy will depend on a variety of factors, including, for example, the route of administration,the condition being treated, the species of the patient, any potential interactions between the active ingredients when combined into a single composition, any interactions between the active ingredients when they are administered to the animal patient, and various other factors known to physicians (in the context of human patients), veterinarians (in the context of non-human patients), and others skilled in the art.
[0595] PHARMACEUTICAL COMPOSITIONS
[0596] There is provided a method of treatment of a condition where inhibition of NNMT is required, which method comprises administration of a therapeutically effective amount of an orotate crystalline addition salt of a compound of Formula (I) to a person suffering from, or susceptible to, such a condition.
[0597] The orotate crystalline addition salts of compounds of Formula (I) will normally be administered via the oral, topical, parenteral, intravenous, intramuscular, subcutaneous or in other injectable ways, buccal, rectal, vaginal, transdermal and / or nasal route and / or via inhalation, in the form of pharmaceutical preparations comprising the active ingredient or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated and the route of administration, the compositions may be administered at varying doses. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, Pharmaceuticals - The Science of Dosage Form Designs, M. E. Aulton, Churchill Livingstone, 2nd Ed. 2002.
[0598] Suitable daily doses of the compounds of Formula (I) in therapeutical treatment of humans are about 0.0001-100 mg / kg body weight.
[0599] Oral formulations are preferred, particularly tablets or capsules which may be formulated by methods known to those skilled in the art to provide doses of the active compound in the range of 0.007 mg to 700 mg.
[0600] The optimum dosage and frequency of administration will depend on the particular condition being treated and its severity; the species of the patient; the age, sex, size and weight, diet, and general physical condition of the particular patient; brain / bodyweight ratio; other medication the patient may be taking; the route of administration; the formulation; and various other factors known to physicians and others skilled in the art.
[0601] According to a further aspect there is thus provided a pharmaceutical formulation comprising orotate crystalline addition salt of a compound of Formula (I) in admixture with a pharmaceutically acceptable adjuvant, diluent and / or carrier. The orotate crystalline addition salts of compounds of Formula (I) may be present in the pharmaceutical formulation in a concentration from 0.1 to 99.5%, such as from 0.5 to 95%, by weight of the total formulation.
[0602] PREPARATION OF THE COMPOUNDS
[0603] It will be appreciated by those skilled in the art that in the processes certain functional groups such as hydroxyl or amino groups in the reagents may need to be protected by protecting groups. Thus, the preparation of the compounds of Formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups.
[0604] The protection and deprotection of functional groups is described in Protective Groups in Organic Synthesis, 4thEd, T. W. Greene and P. G. M. Wuts, Wiley-Interscience (2006) and Protecting Groups, 3rdEd, P. J. Kocienski, Georg Thieme Verlag (2005).
[0605] The skilled person will recognize that at any stage of the preparation of the orotate crystalline addition salts of compounds of Formula (I), mixtures of isomers (e.g. racemates) of compounds may be utilized. At any stage of the preparation, a single stereoisomer may be obtained by isolating it from a mixture of isomers (e.g., a racemate) using, for example, chiral chromatographic separation.
[0606] The term “pharmaceutically acceptable” is used to characterize a moiety (e.g. a salt, dosage form, or excipient) as being appropriate for use in accordance with sound medical judgment. In general, a pharmaceutically acceptable moiety has one or more benefits that outweigh any deleterious effect that the moiety may have. Deleterious effects may include, for example, excessive toxicity, irritation, allergic response, and other problems and complications.It is also to be understood that certain orotate crystalline addition salts of compounds of Formula (I) may exist in solvated form, e.g. hydrates.
[0607] In a further embodiment, certain orotate crystalline addition salts of compounds of Formula (I) may exist as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. Certain orotate crystalline addition salts of compounds of Formula (I) may also contain linkages (e.g. carboncarbon bonds, carbon-nitrogen bonds such as amide bonds) wherein bond rotation is restricted about that particular linkage, e.g. restriction resulting from the presence of a ring bond or double bond. Stereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallization, or the stereoisomers may be made by stereoselective synthesis.
[0608] In a further embodiment, the orotate crystalline addition salts of compounds of Formula (I) encompass any isotopically-labelled (or “radio-labelled”) derivatives of a compound of Formula (I). Such a derivative is a derivative of a compound of Formula (I) wherein one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature. Examples of isotopes that may be incorporated include
[0609]
[0610] (also written as “D” for deuterium).
[0611] In a further embodiment, the compounds of Formula (I) may also contain various tautomeric forms. It is to be understood that all such tautomeric forms are encompassed.
[0612] In a further embodiment, the orotate crystalline addition salts of compounds of Formula (I) may be administered in the form of a prodrug which is broken down in the human or animal body to give a compound of the Formula (I).
[0613] Various forms of prodrugs are known in the art. For examples of prodrug derivatives, see: Nature Reviews Drug Discovery 2008, 7, 255 and references cited therein.
[0614] Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.PHARMACOLOGICAL ACTIVITY
[0615] The pharmacological activity of compounds disclosed herein was tested in the following screen (Test A).
[0616] Test A - Cellular assay of human NNMT in RPTEC / TERT1 cells Cryopreserved RPTEC / TERT1 cells (CRL-4031 from ATCC) endogenously expressing human NNMT were thawed, centrifuged and diluted into cell media (DMEM / F-12 + GlutaMAX-I (Gibco 31331-028), containing 0.1 mg / ml Genectin (Gibco, 10131027)). The cell suspension was dispensed to 384-well microplates (Corning 3764) containing compounds dissolved in DMSO, using a Multidrop Combi (ThermoFisher; 8000 cells per well, final assay volume 30 µl, 0.3% final DMSO). The microplates were incubated in a cell incubator (37 °C in humidified 5% CO2 / air atmosphere). After 24 h the cell media was removed and cells were washed with PBS using a BlueWasher (BlueCatBio GmbH, Germany), followed by addition of 20 pl water (Multidrop Combi) and freezing on dry ice. Plates were stored at -20 °C until sample preparation for the LC-MS analysis. Cellular NNMT activity was determined measuring 1-MNA (1 -methylnicotinamide) levels using a LC-MS detection system. Frozen cell lysates were thawed and diluted into methanol / acetonitrile (50 / 50) containing 1-MNA-D3 (M323237, TRC, Toronto, Canada) and centrifuged at 2600 g for 30 minutes prior to sampling in the API 5000 LC / MS / MS system with Qjet (Applied biosystems; sample volume of 10 µl, Phase A: 5mM acetic acid / 0.2% formic acid, Phase B: acetonitrile; Column: Xbridge amide 3.5 mm 2.1 x 50 mm column, Waters / Bridge 186004859). 1-MNA levels were quantified as the area under the curve of the 1 -MNA peak and normalized using 1-MNA-D3. Data processing, assay quality control and concentration response curve fitting was analyzed using Genedata Screener (Basel, Switzerland). Compound potencies were determined from 10-point concentration response curves using 3-fold dilution steps, with a final assay concentration ranging from 30 mM down to 15 nM. The Z’-factor was between 0.5-0.8.
[0617] The IC50 values (NNMT) for the Example compounds are set forth in Table 1 herein below.Table 1
[0618]
[0619] EXAMPLES
[0620] The following examples are non-limiting examples.
[0621] GENERAL CONDITIONS
[0622] (i) operations were carried out at room temperature (rt), i.e. in the range 17 to 25 °C and under an atmosphere of an inert gas such as N2(g) unless otherwise stated; optionally reactions were carried out using a MBRAUN UNILab Plus ECO or a MBRAUN UNILab SP Eco glovebox workstation or a KitAlysis™ Benchtop Inertion Box from Sigma-Aldrich, in which case it is indicated;
[0623] (ii) where reactions refer to being degassed or purged, this can be performed for example by purging the reaction solvent with a constant flow of nitrogen for a suitable period of time (for example 5 to 10 min) or by repeatedly evacuating the vessel and backfill with appropriate inert atmosphere (for example nitrogen (g) or argon (g));
[0624] (iii) where reactions refer to the use of a microwave reactor, one of the following microwave reactors were used: Biotage Initiator, Personal Chemistry Emrys Optimizer, Personal Chemistry Smith Creator or CEM Explorer;(iv) in general, the course of reactions was followed by thin layer chromatography (TLC) and / or analytical high performance liquid chromatography (HPLC or UPLC) which was usually coupled to a mass spectrometer (LCMS).
[0625] (v) when necessary, organic solutions were dried over anhydrous MgSO4or Na2SO4, or by using ISOLUTE® Phase Separator, and work-up procedures were carried out using traditional phase separating techniques. When a drying agent such as e.g. MgSO4or Na2SO4is used for drying an organic layer, it is understood that said organic layer is filtered before concentration of said layer.
[0626] (vi) It is understood that washing solutions used in the work-up procedures or reagent used for acidifying such as e.g. Brine, NaHCO3, NH4Cl, HCl, NaH2PO4are presumed to be aqueous solutions unless otherwise stated
[0627] (vii), evaporations were carried out either by rotary evaporation in vacuo or in a Genevac HT-4 / EZ-2 or Biotage V10;
[0628] (viii) unless otherwise stated, flash column chromatography was performed on straight phase silica, using either Merck Silica Gel (Art. 9385) or prep-packed cartridges such as Biotage® SNAP cartridges (40-63 pm silica, 4-330 g), Biotage® Sfar Silica HC D cartridges (20 pm, 10-100 g), Interchim puriFlash™ cartridges (25 pm, 4-120 g), Interchim puriFlash™ cartridges (50 pm, 25-330 g), Grace™ GraceResolv™ Silica Flash Cartridges (4-120 g) or Agela Flash Colum Silica-CS cartridges (80-330 g), or on reversed phase silica using Agela Technologies C-18, spherical cartridges (20-35 pm, 100 A, 80-330 g), manually or automated using a Grace Reveleris® X2 Flash system or similar system;
[0629] (ix) preparative reverse phase HPLC and preparative reverse phase SFC were performed using standard HPLC and SFC instruments, respectively, equipped with either a MS and / or UV triggered fraction collecting instrument, using either isocratic or a gradient of the mobile phase as described in the experimental section, and one of the following methods as described below; PrepMethod A;
[0630] The compound was purified by preparative HPLC on a XBridge™ Shield C18 column (5 pm, 150x30 mm ID) using a gradient of MeCN in a H2O / NH4CO3(10 mM) / NH3(0.1%, aq) buffer system as mobile phase; PrepMethod B; The compound was purified by preparative SFC on a Kromasil XT, (10 pM, 250 x 50 mm ID) using MeOH / NH3(100 / 20 mM) in CO2 as mobile phase; PrepMethodC; The compound was purified by preparative SFC on a Kromasil CN, (5 pM, 250 x 30 mm ID) using EtOH / DEA (100 / 20 mM) in CO2 as mobile phase;
[0631] PrepMethod D; The compound was purified by preparative HPLC on a XBridge™ C18 column (10 pm, 250^50 mm ID) using a gradient of MeCN in H2O / MeCN / NH3(95 / 5 / 0.2) as mobile phase; PrepMethod E; The compound was purified by preparative HPLC on a XBridge™ Cl 8 OBD column (5 pm, 150x30 mm ID) using a gradient of MeCN in H2O / NH4HCO3(10 mM) as mobile phase; PrepMethod F; The compound was purified by preparative SFC on a SuperSep 1, Viridis 2-EP column (5 pm, 250x30) using MeOH / NH3(100 / 20 mM) in CO2 as mobile phase.
[0632] Relevant fractions were collected, combined and freeze-dried to give the purified compound or relevant fractions were collected, combined and concentrated at reduced pressure, extracted with DCM or EtOAc, and the organic phase was dried either over Na2SO4 or by using a phase-separator, and then concentrated at reduced pressure to give the purified compound.
[0633] (x) chiral preparative chromatography was carried out using HPLC or SFC on a standard HPLC or SFC instruments, respectively, and using either isocratic or gradient run with mobile phase as described in the experimental section;
[0634] (xi) yields, where present, are not necessarily the maximum attainable, and when necessary, reactions were repeated if a larger amount of the reaction product was required;
[0635] (xii) where certain compounds were obtained as an acid-addition salt, for example a mono-hydrochloride salt or a di-hydrochloride salt, the stoichiometry of the salt was based on the number and nature of the basic groups in the compound, the exact stoichiometry of the salt was generally not determined, for example by means of elemental analysis data;
[0636] (xiii) in general, the structures of the end-products of the Formula (I) were confirmed by nuclear magnetic resonance (NMR) and / or mass spectral techniques; proton NMR chemical shift values were measured on the delta scale using Bruker Avance III 300, 400, 500 and 600 spectrometers, operating at1H frequencies of 300, 400, 500 and 600 MHz, respectively. The experiments were typically recorded at 25 °C. Chemical shifts are given in ppm with the solvent as internalstandard. Protons on heteroatoms such as NH and OH protons are only reported when detected in NMR and can therefore be missing. In certain instances, protons can be masked or partially masked by solvent peaks and will therefore either be missing and not reported or reported as multiplets overlapping with solvent. The following abbreviations have been used (and derivatives thereof, e.g. dd, doublet of doublets, ddd, doublet of doublet of doublets, dt, doublet of triplets, dq, doublet of quartet etc.): s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; qn, quintet; p, pentet; h, heptet. It is understood, where the NMR spectra contains residual impurities and / or residual solvent(s), this is not reported unless it coincides or partially coincides with peaks of Intermediates and / or structures of Formula (I), in which case they are reported as multiplets, partially overlapping with said solvent or impurity and the integral is omitted. In some cases, the structures of the end-products of the Formula (I) might appear as rotamers in the NMR-spectrum, in which instances only peaks of the major rotamer are reported. In some cases, the structures of the end-products of Formula (I) might appear as rotamers in more equal portions, in such instances the peaks of such rotamers are either reported as multiplets, if the signals of said rotamers are partially overlapping, or as individual peaks, if the signals of said rotamers are well separated. Electrospray mass spectral data were obtained using a Waters Acquity UPLC coupled to a Waters single quadrupole mass spectrometer or similar equipment, acquiring both positive and negative ion data, and generally, only ions relating to the parent structure are reported; high resolution electrospray mass spectral data were obtained using a Waters XEVO qToF mass spectrometer or similar equipment, coupled to a Waters Acquity UPLC, acquiring either positive and negative ion data, and generally, only ions relating to the parent structure are reported
[0637] (xiv) intermediates were not necessarily fully purified but their structures and purity were assessed by TLC, analytical HPLC / UPLC, and / or NMR analysis and / or mass spectrometry;
[0638] (xv) unless stated otherwise compounds containing an asymmetric carbon and / or sulfur atom were not resolved;(xvi) in general Examples and Intermediate compounds are named using ChemDraw Professional version 22.2.0 from PerkinElmer. ChemDraw Professional version 22.2.0 generates the names of chemical structures using the Cahn-Ingold-Prelog (CIP) rules for stereochemistry and follows IUPAC rules as closely as possible when generating chemical names. Stereoisomers are differentiated from each other by stereodescriptors cited in names and assigned in accordance with the CIP rules.
[0639] (xvii) The X-ray diffraction analysis was performed according to standard methods, which can be found in e.g. Kitaigorodsky, A. I. (1973), Molecular Crystals and Molecules, Academic Press, New York; Bunn, C. W. (1948), Chemical Crystallography, Clarendon Press, London; or Klug, H. P. & Alexander, L. E. (1974), X-ray Diffraction Procedures, John Wiley & Sons, New York.
[0640] The standard Bragg-Brentano powder X-ray diffraction was recorded with a theta-two theta scan axis and in one dimensional scan with Rigaku Miniflex 600 (wavelength of X-rays 1.5418 A nickel-filtered Cu Karadiation, 40 kV, 15 mA) equipped with D / Tex Ultra detector. Automatic variable anti scattering slits were used and the samples were rotated at 30 revolution per minute during measurement. Samples were scanned from 3 - 40° 2-theta using a 0.01° and 2° / min step width and scan speed respectively.
[0641] The capillary transmission powder X-ray diffraction was recorded with a two theta scan axis and in one dimensional scan with Rigaku SmartLab (nickel-Filtered Cu Karadiation, 40 kV, 50 mA) equipped with D / tex Ultra 250 detector and CBO-E optic. The samples were rotated at 30 revolution per minute during measurement. Samples were scanned from 3-40° 2-theta using a 0.01° and 0.2 ° / min step width and scan speed, respectively. The powder samples were packed in long glass capillary with 0.9 mm outer diameter.
[0642] It is known in the art that an X-ray powder diffraction pattern may be obtained which has one or more measurement errors depending on measurement conditions (such as equipment, sample preparation or machine used). In particular, it is generally known that intensities in an X-ray powder diffraction pattern may fluctuate depending on measurement conditions and sample preparation. Forexample, persons skilled in the art of X-ray powder diffraction will realise that the relative intensities of peaks may vary according to the orientation of the sample under test and on the type and setting of the instrument used. Persons skilled in the art of X-ray powder diffraction will realise that the relative intensity of peaks can be affected by, for example, grains above 30 microns in size and non -unitary aspect ratios which may affect analysis of samples. The skilled person will also realise that the position of reflections can be affected by the precise height at which the sample sits in the diffractometer and the zero calibration of the diffractometer. The surface planarity of the sample may also have a small effect. Hence a person skilled in the art will appreciate that the diffraction pattern data presented herein is not to be construed as absolute and any crystalline form that provides a power diffraction pattern substantially identical to those disclosed herein fall within the scope of the present disclosure (for further information see Jenkins, R & Snyder, R. L. ‘Introduction to X-Ray Powder Diffractometry’ John Wiley & Sons, 1996). Generally, a measurement error of a diffraction angle in an X-ray powder diffractogram may be approximately plus or minus 0.1° 2-theta, and such a degree of a measurement error should be taken into account when considering the X-ray powder diffraction data. Furthermore, it should be understood that intensities might fluctuate depending on experimental conditions and sample preparation (e.g. preferred orientation). The following definitions have been used for the relative intensity (%): 81 - 100%, vs (very strong); 41 - 80%, str (strong); 21 - 40%, med (medium); 10 - 20%, w (weak); 1 - 9%, vw (very weak), (xviii) in addition to the ones mentioned above, the following abbreviations and units have been used:
[0643]
[0644]
[0645]
[0646] Intermediate 1
[0647] 5-Methoxy-l-methyl- pyrazole-4-carbonyl chloride
[0648]
[0649] 5-Methoxy-l-methyl-IT / -pyrazole-4-carboxylic acid (0.131 g, 0.8 mmol) was suspended in DCM (2.2 mL). Oxalyl chloride (0.143 mL, 1.60 mmol) was added, and the mixture was cooled in an ice-bath. DMF (6.19 pL, 0.08 mmol) was added and the reaction mixture was stirred at rt for 1 h. The mixture was concentrated under reduced pressure and co-evaporated with DCM to afford the title compound (0.137 g, 98%). 'H NMR (500 MHz, DMSO-6) 3.60 (3H, s), 4.06 (3H, s), 7.63 (1H, s).
[0650] Intermediate 2
[0651] tert-Butyl 4-(3 -(5-methoxy- 1 -methyl - I rt-pyrazol -4-yl)-3 -oxoprop- 1 -yn- 1 -yl)piperidine-l -carboxylate
[0652] Pd(PPh3)2Cl2(0.017 g, 0.02 mmol) was added to a solution of tert-butyl 4-ethynylpiperidine-1 -carboxylate (0.103 g, 0.493 mmol), 5 -methoxy- 1 -methyl- \H-pyrazole-4-carbonyl chloride Intermediate 1 (0.129 g, 0.74 mmol), Cui (4.7 mg, 0.02 mmol) and TEA (0.412 mL, 2.96 mmol) in THF (0.85 mL) and toluene (0.85 mL). The reaction mixture was stirred under an atmosphere of N2(g) at rt for 3 h. DCM (7 mL) and sat NaHCCL (aq, 7 mL) were added. The mixture was stirred, filtered through a phase separator, and concentrated under reduced pressure. Thecrude residue was purified by straight phase flash chromatography on silica (gradient 0-40% (EtOAc / 4M NH3 in MeOH (9 / 1)) in DCM) to give the title compound (0.038 g, 22%). MS (ESI) m / z [(M-Boc)+H]+248.1. 'HNMR (500 MHz, CDCl3) 1.46 (9H, s), 1.64 - 1.75 (2H, m), 1.86 - 1.94 (2H, m), 2.76 - 2.87 (1H, m), 3.22 (2H, ddd), 3.67 (3H, s), 3.70 - 3.80 (2H, m), 4.21 (3H, s), 7.86 (1H, s).
[0653] Intermediate 3
[0654] tert-Butyl 4-(5' -methoxy- 1 '-methyl-1 '77,277-13, 4'-bipyrazol1-5-yl)piperi dine-1-carb oxy late
[0655] tert-Butyl 4-(3 -(5-methoxy- 1 -methyl - IH-pyrazol -4-yl)-3 -oxoprop- 1 -yn- 1 -yl)piperidine-l -carboxylate Intermediate 2 (0.037 g, 0.11 mmol) was dissolved in 99.5% EtOH (0.7 mL). 64% Hydrazine hydrate (aq, 0.026 mL, 0.53 mmol) was added, and the reaction mixture was stirred at rt overnight. DCM and NaHCCL (aq) were added, the mixture was stirred, filtered through a phase separator, and concentrated to yield the title compound (0.039 g). Used as such in the next step. MS (ESI) m / z [M+H]+362.3.
[0656] Intermediate 4
[0657] 5'-Methoxy-l '-methyl-5-(piperidin-4-yl)-l '77,277-3, 4'-bipyrazole
[0658] TFA (15.77 mg, 0.14 mmol) was added to a solution of tert-butyl 4-(5’-m ethoxy -r-methyl-r77,277-[3,4’-bipyrazol]-5-yl)piperidine-l-carboxylate Intermediate 3 (50 mg, 0.14 mmol) in DCM (1 mL) at 10 °C and the reaction mixture was stirred for 2 h. The mixture was concentrated to grant the TFA salt of the title compound (40 mg). MS (ESI) m / z [M+H]+262.1.
[0659] Intermediate 5
[0660] 2-((3-Acetyl-6-methylpyri din-2 -yl)amino)-2-oxoethyl acetate
[0661] TEA (19.31 mL, 138.5 mmol) was added to 1 -(2-amino-6-m ethylpyri din-3 -yl)ethan-l-one (10.4 g, 69.25 mmol) and 2-chloro-2-oxoethyl acetate (9.45 g, 69.25 mmol) in DCM (200 mL) at 0°C over a period of 5 min. The reaction mixture was stirred at 15 °C for 16 h. The solvent was removed under reducedpressure. The crude solid was triturated with 20% EtOAc in petroleum ether and filtered. The precipitate was washed with 20% EtOAc in petroleum ether and dried under vacuum to grant the title compound (17.2 g, 99%) as a brown solid. MS (ESI) m / z [M+H]+372.3.
[0662] Intermediate 6
[0663] (4,7-Dimethylpyridol2,3-d1pyrimidin-2-yl)methyl acetate
[0664] A solution of 2-((3-acetyl-6-m ethylpyri din-2 -yl)amino)-2-oxoethyl acetate Intermediate 5 (247 mg, 0.99 mmol) and NEUOAc (380 mg, 4.93 mmol) in AcOH (2.47 mL) was heated in a microwave reactor at 130 °C for 40 min. The solution was concentrated and the residue was purified using straight phase flash chromatography on silica (gradient: 50-100% EtOAc in heptane) to grant the title compound (89 mg, 39%) as a yellow oil. MS (ESI) m / z [M+H]+232.2.
[0665] Intermediate 7
[0666] (4.7-Dimethylpyridor2.3- ]pyrimidin-2-yl)methanol
[0667] NaOMe (30 wt.% in MeOH, 397 pL, 2.14 mmol) was added to a solution of (4,7-dimethylpyrido[2,3-d]pyrimidin-2-yl)methyl acetate Intermediate 6 (495 mg, 2.14 mmol) in MeOH (6.62 mL). The reaction mixture was stirred at rt for 10 min followed by addition of AcOH (123 pL, 2.14 mmol) and then concentrated. The residue was dissolved in DCM (and a drop of MeOH), filtered using a syringe filter and purified by straight phase chromatography on silica (gradient: 0-20% MeOH in EtOAc) to grant the title compound (306 mg, 75%) as a slightly yellow solid. MS (ESI) m / z [M+H]+190.2.
[0668] Intermediate 8
[0669] (4.7-Dimethylpyridor2.3- ]pyrimidin-2-yl)methyl methanesulfonate
[0670] A solution of methanesulfonic anhydride (337 mg, 1.93 mmol) in DCM (2 mL) was added to a solution of (4,7-dimethylpyrido[2,3-J]pyrimidin-2-yl)methanol Intermediate 7 (305 mg, 1.61 mmol) and DIPEA (421 pL, 2.42 mmol) in DCM (6 mL) at 0 °C. The reaction mixture was stirred for 15 min and then quenched with sat NaHCOs (aq) and diluted with DCM. The aqueous layer was extractedwith DCM and the combined organic layer was washed once with water and once with brine before drying over MgSC The organic layer was filtered and concentrated to afford the title compound (424 mg, 98%) as a yellow solid. MS (ESI) m / z [M+H]+268.1.
[0671] Intermediate 9
[0672] 2-((4-(5'-Methoxy-l'-methyl-17L2Z / -r3,4'-bipyrazol]-5-yl)piperidin-l-yl)methyl)-
[0673]
[0674] 5'-Methoxy-l'-methyl-5-(piperidin-4-yl)-1 / ,2J7-3,4'-bipyrazole, TFA Intermediate 4 (400 mg, 1.11 mmol) was added to (4,7-dimethylpyrido[2,3- ]pyrimidin-2-yl)methyl methanesulfonate Intermediate 8 (357 mg, 1.34 mmol) and K2CO3 (1.54 g, 11.14 mmol) in MeCN (8 mL) at 10 °C. The resulting solution was stirred at 60 °C for 16 h. The reaction mixture was poured into water and extracted with DCM. The combined organic layers were dried over Na2SO4, filtered and concentrated. The crude residue was purified by preparative HPLC, PrepMethod P, (gradient: 10-38%), to grant the title compound (400 mg, 83%) as a yellow solid. 'H NMR (300 MHz, DMSO-6) 8 12.41 (s, 1H), 8.59 (d, 1H), 7.59 (d, 1H), 7.52 (s, 1H), 6.12 (s, 1H), 3.88 (s, 3H), 3.80 (s, 2H), 3.62 (s, 3H), 3.02 (m, 2H), 2.88 (s, 3H), 2.71 (s, 3H), 2.59 (s, 1H), 2.26 (t, 2H), 1.85 (m, 2H), 1.65 (q, 2H). HRMS (ESI) m / z [M+H]+calcd for C23H29N8O: 433.2458, found: 433.2480.
[0675] Intermediate 10
[0676] tert-Butyl 4-ethynyl-4-methoxypiperidine-l -carboxylate
[0677] / c / V-Butyl 4-ethynyl-4-hydroxypiperidine-l -carboxylate (8.9 g, 37.53 mmol) was dissolved in anhydrous DMF (100 mL) and NaH (60% wt% in mineral oil, 1.876 g, 46.91 mmol) was added in portions over 5 min at rt under an atmosphere of N2 (g). The reaction mixture was stirred at rt for 25 min, then Mel (2.92 mL, 46.91 mmol) was added dropwise over 10 min under an atmosphere of N2 (g). The reaction mixture was stirred at rt for 1 h. The mixture was poured onto ice-water and when reached rt extracted with EtOAc. The organic layer was dried over MgSCU, filtered and concentrated under reduced pressure. The crude residue was purified by straight phase flash chromatography on silica (gradient 5-40% EtOAcin heptane) to give the title compound (6.6 g, 74%) as colorless oil.1H NMR (500 MHz, CDCl3) 1.45 (9H, s), 1.66 - 1.74 (2H, m), 1.85 - 1.95 (2H, m), 2.52 (1H, s), 3.24 - 3.33 (2H, m), 3.38 (3H, s), 3.64 - 3.76 (2H, m).
[0678] Intermediate 11
[0679] tert-Butyl 4-(3 -( 1, 5 -dimethyl- 1 H-pyrazol -4-yl)-3 -oxoprop- 1 -yn- 1 -yl)-4-methoxypiperidine-1 -carboxylate
[0680] Zc / V-Butyl 4-ethynyl-4-methoxypiperidine-l -carboxylate Intermediate 10 (6.6 g, 27.58 mmol), l,5-dimethyl-U / -pyrazole-4-carbonyl chloride (6.56 g, 41.37 mmol), Cui (0.263 g, 1.38 mmol) and TEA (23.06 mL, 165.47 mmol) were mixed in THF (50 mL) and toluene (50 mL). Pd(PPh3)2C12 (0.988 g, 1.38 mmol) was added and the reaction mixture was stirred under an atmosphere of N2 (g) at rt for 2 d. DCM (250 mL) and sat NaHCCL (aq) (250 mL) were added and the mixture was stirred, filtered through a phase separator, and concentrated to give the crude title compound (15 g). MS (ESI) m / z [(M-Boc)+H]+262.1.
[0681] Intermediate 12
[0682] tert-Butyl 4-(l'.5'-dimethyl-17L2J / -r3.4'-bipyrazol]-5-yl)-4-methoxypiperidine-l-carboxylate
[0683] Zc / 7-Buty 1 4-(3 -( 1, 5 -dimethyl- 177-pyrazol -4-yl)-3 -oxoprop- 1 -yn- 1 -yl)-4-methoxypiperidine-1 -carboxylate Intermediate 11 (9.76 g, 27 mmol) was suspended in 99.5% EtOH (200 mL). The mixture was cooled in an ice-bath and 64% hydrazine hydrate (aq, 6.57 mL, 135.00 mmol) was added. The reaction mixture was stirred at rt for 2 h. The mixture was poured into water (200 mL) and sat NaHCCL (aq) (40 mL). The mixture was concentrated and the remaining aqueous layer was extracted with EtOAc. The organic layer was dried over Na2SC>4, filtered, and concentrated under reduced pressure. The crude residue was purified by straight phase flash chromatography on silica (gradient 40-100% (EtOAc / MeOH (9 / 1)) to give the title compound (6.3 g, 62%). MS (ESI) m / z [M+H]+376.4. 'H NMR (500 MHz, DMSO-6) 1.40 (9H, s), 1.77 - 2.06 (4H, m), 2.30 -2.47 (3H, m), 2.95 (3H, s), 3.10 - 3.31 (2H, m), 3.42 - 3.66 (2H, m), 3.76 (3H, s), 6.30 (1H, s), 7.61 (1H, s), 12.68 (1H, s).Intermediate 13
[0684] 5-(4-Methoxypiperidin-4-yl)-l\5'-dimethyl-17L2J / -3,4'-bipyrazole
[0685] Zc / V-Butyl 4-(l(5'-dimethyl-17 / ,2J / -[3,4'-bipyrazol]-5-yl)-4-methoxypiperidine-l-carboxylate Intermediate 12 (5.8 g, 15.45 mmol) was dissolved in EtOAc (50 mL). 6 M HC1 in IPA (25.7 mL, 154.47 mmol) was added dropwise, and the reaction mixture was stirred at 50 °C for 3 h. The mixture was concentrated under reduced pressure to yield the HCl-salt of the title compound (6.06 g). MS (ESI) m / z [M+H]+276.2. *HNMR (500 MHz, DMSO-6) 2.15 - 2.33 (4H, m), 2.41 (3H, s), 2.96 (3H, s), 3.00 - 3.13 (4H, m), 3.78 (3H, s), 6.41 - 6.48 (1H, m), 7.73 - 7.83 (1H, m), 9.33 (2H, s).
[0686] Intermediate 14
[0687] 2-((4-(l'.5'-Dimethyl-l'J / .2J / -r3.4'-bipyrazol1-5-yl)-4-methoxypiperidin-l-yl)methyl)-4-methylquinazoline
[0688] A mixture of 5-(4-methoxypiperidin-4-yl)-l',5'-dimethyl-17 / ,2J / -3,4'-bipyrazole, HCl-salt Intermediate 13 (5.36 g, 15.4 mmol), 2-(chloromethyl)-4-methylquinazoline (2.82 g, 14.63 mmol) and K2CO3 (17.03 g, 123.20 mmol) in MeCN (100 mL) and stirred at 60 °C for 24 h. After cooling to rt, solids were filtered off and washed with MeCN. The filtrate was concentrated under reduced pressure and the crude compound was purified by preparative SFC, PrepMethod NN, (isocratic 25%), to give the title compound (2.6 g, 39%) as tan solid. 'H NMR (500 MHz, Methanol-t / 4) 2.12 - 2.24 (4H, m), 2.43 (3H, s), 2.67 - 2.86 (4H, m), 2.98 (3H, s), 3.06 (3H, s), 3.82 (3H, s), 3.91 (2H, s), 6.33 (1H, s), 7.64 (1H, s), 7.72 (1H, ddd), 7.94 - 8.01 (2H, m), 8.23 - 8.29 (1H, m). HRMS (ESI) m / z [M+H]+calcd for C24H30N7O: 432.2506, found: 432.2508.
[0689] Intermediate 15
[0690] tert-Butyl 4-hydroxy-4-((trimethylsilyl)ethynyl)piperidine-l -carboxylate Ethynyltrimethylsilane (5.94 mL, 42.05 mmol) was dissolved in THF (118 mL) and cooled to -78 °C. 2.5 M / / BuLi in hexane (16.82 mL, 42.05 mmol) was added dropwise and the reaction mixture was stirred at -78 °C for 40 min and thenallowed to reach rt. After 70 min, the reaction mixture was cooled to -78 °C and a solution of tert-butyl 4-oxopiperidine-l -carboxylate (7.12 g, 35.04 mmol) in THF (72 mL) was added dropwise. The mixture was warmed to rt and stirred for 3 h. The reaction was quenched with sat NH4CI (aq) followed by addition of EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc. The combined organic extracts were washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. Heptane was added to the residue and the mixture was heated to 45 °C and sonicated. White solid precipitated after cooling to rt. The solids were filtered off and washed with cold heptane. The mother liquor was concentrated and purified by straight phase flash chromatography on silica (gradient: 2-32% EtOAc in heptane) and the product containing fractions were collected and combined with the precipitate to give the title compound (9.444g, 91%). *HNMR (500 MHz, CDCl3, 18 °C) 50.17 (9H, s), 1.45 (9H, s), 1.67 (2H, ddd), 1.83 - 2.10 (3H, m), 3.20 (2H, ddd), 3.76 - 3.84 (2H, m).
[0691] Intermediate 16
[0692] tert-Butyl 4-((trimethyl silyl )ethynyl)-3.6-dihydropyridine- l(27 / )-carboxylate tert-Butyl 4-hydroxy-4-((trimethylsilyl)ethynyl)piperidine-l -carboxylate Intermediate 15 (12.775 g, 42.95 mmol) was dissolved in DCM (120 mL) and cooled in an ice-bath. DMAP (5.77 g, 47.24 mmol) was added, followed by TEA (17.96 mL, 128.84 mmol) and a dropwise addition of methanesulfonyl chloride (10.04 mL, 128.84 mmol). The reaction mixture was allowed to warm to rt and stirred for 18 h. The mixture was poured into water. The layers were separated and the aqueous layer was extracted with DCM. The combined organic extracts were washed with IM HC1 and sat NaHCCL (aq), and then dried over MgSCh, filtered, and concentrated under reduced pressure. The crude residue was dissolved in heptane and filtered. The solids filtered off were washed with heptane. The combined filtrate was concentrated to afford the title compound (12.18 g). 'H NMR (500 MHz, CDCl3, 18 °C) 50.17 (9H, s), 1.45 (9H, s), 2.19 - 2.28 (2H, m), 3.47 (2H, t), 3.92 - 3.97 (2H, m), 6.06 (1H, s).Intermediate 17
[0693] rac-te / 7-Butyl (lA,6A)-6-((trimethylsilyl)ethynyl)-7-oxa-3-azabicyclol4, 1,01heptane-3 -carboxylate
[0694] Zc / V-Butyl 4-((trimethyl silyl )ethynyl)-3,6-dihydropyridine-l(2 / / )-carboxylate Intermediate 16 (8.035 g, 28.75 mmol) was dissolved in DCM (170 mL) and the flask was kept in the dark and cooled in an ice-bath. mCPBA (19.33 g, 86.26 mmol) was dissolved in DCM (100 mL) and added dropwise via a dropping funnel. The reaction mixture was stirred at rt overnight. The mixture was diluted with DCM and water and the layers were separated. The aqueous layer was extracted with DCM. The combined organic layers were washed with water and brine, filtered through a phase separator, and concentrated under reduced pressure. The crude residue was purified by straight phase flash chromatography on silica (gradient 3-12% EtOAc in heptane) to give the title compound (4.30 g, 51%) as white solid. 'H NMR (500 MHz, CDCl3, 25 °C) 50.17 (9H, s), 1.44 (9H, s), 2.05-2.26 (2H, m), 2.97-3.08 (1H, m), 3.35-3.46 (1H, m), 3.46-3.68 (2H, m), 3.84-4.06 (1H, m).
[0695] Intermediate 18
[0696] rac-te / 7-Butyl (3 A.4M-3 -hydroxy -4-m ethoxy -4-((trimethylsilyl)ethynyl)piperidine-l-carboxylate
[0697] rac-tert-Butyl (lA,6A)-6-((trimethylsilyl)ethynyl)-7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate Intermediate 17 (4.297 g, 14.54 mmol) was dissolved in MeOH (135 mL) and TsOH (5.53 g, 29.09 mmol) was added at rt. The reaction mixture was stirred for 1 h. The reaction was quenched with sat NaHCCL (aq) and diluted with EtOAc and water. The layers were separated, and the aqueous layer extracted with EtOAc, dried over MgSO4, filtered, and concentrated under reduced pressure to afford the title compound (3.73 g, 78%) as yellow oil. 'H NMR (500 MHz, CDCl3, 25 °C) 50.20 (9H, s), 1.44-1.58 (11H, m), 2.08 (1H, ddd), 3.04-3.16 (2H, m), 3.41 (3H, s), 3.53 (1H, dd), 3.79-3.87 (1H, m), 3.96 (1H, ddd).
[0698] Intermediate 19rac-te / 7-Butyl (3A,4M-4-ethynyl-3-hydroxy-4-methoxypiperidine-l -carboxylate rac-tert-Buty 1 (3 / , 4S)-3 -hydroxy -4 -methoxy -4 -((trimethylsilyl)ethynyl)piperidine-l-carboxylate Intermediate 18 (3.726 g, 11.38 mmol) was dissolved in MeOH (52 mL) and K2CO3 (3.14 g, 22.75 mmol) was added. The reaction mixture was stirred at rt overnight, filtered and the filtrate was concentrated under reduced pressure. The crude residue was dissolved in EtOAc and washed with sat NaHCCf (aq). The organic layer was dried over ISfeSCU, filtered and concentrated. The crude residue was purified by straight phase flash chromatography on silica (gradient 3-60% EtOAc in heptane) to give the title compound (2.279 g, 78%) as colorless oil. 'H NMR (500 MHz, CDCl3, 25 °C) 5 1.45 (9H, s), 1.57 (1H, ddd), 2.11 (1H, ddd), 2.63 (1H, s), 3.06-3.2 (2H, m), 3.42 (3H, s), 3.52-3.62 (1H, m), 3.72-3.92 (1H, m), 3.97 (1H, ddd).
[0699] Intermediate 20
[0700] rac-te / 7-Butyl (3RAS)-3 -hydroxy -4-m ethoxy -4-(3 -oxo-3 -( L3,5-trimethyl-IT / -pyrazol-4-yl)prop-l-yn-l-yl)piperidine-l -carboxylate
[0701] rac-tert-Butyl (37?,4S)-4-ethynyl-3-hydroxy-4-methoxypiperidine-l -carboxylate Intermediate 19 (1.475 g, 5.78 mmol) was dissolved in THF (18 mL). Cui (0.055 g, 0.29 mmol), a solution of l,3,5-trimethyl-l / / -pyrazole-4-carbonyl chloride (1.496 g, 8.67 mmol) in THF (9 mL) and Pd(PPh3)2C12 (0.207 g, 0.29 mmol) were added followed by TEA (4.83 mL, 34.66 mmol). The reaction mixture vessel was evacuated and refilled with N2 (g) (x3). The reaction mixture was stirred at rt overnight. DCM and NaHCCf (aq) were added, the layers were separated, and the DCM layer was dried over ISfeSCh, filtered and concentrated under reduced pressure to afford the title compound (2.262 g, 100%). MS (ESI) m / z [M+H]+392.3.
[0702] Intermediate 21
[0703] rac-te / 7-Butyl (3AAM-3-hydroxy-4-methoxy-4-(l' '.5'-trimethyl-17L2 / / -r3.4'-bipyrazol]-5-yl)piperidine-l-carboxylate
[0704] rac-tert-Butyl (3R,4S)-3 -hydroxy -4-m ethoxy -4-(3 -oxo-3 -( 1,3, 5-tri methyl - 17 / -pyrazol-4-yl)prop-l-yn-l-yl)piperidine-l -carboxylate Intermediate 20 (2.262 g,5.78 mmol) was dissolved in EtOH (42 mL) and cooled in an ice-bath. 64% Hydrazine hydrate (aq, 1.401 mL, 28.89 mmol) was added, and the reaction mixture was stirred at rt for 2 h. The mixture was poured into water (50 mL) and NaHCCL (aq, 5 mL) and extracted with EtOAc (3x). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by straight phase flash chromatography on silica (gradient 40-100% (EtOAc / MeOH (9 / 1)) in heptane) to give the title compound (1.700 g, 73%). MS (ESI) m / z [M+H]+406.3. 'HNMR (500 MHz, DMSO-6, 25 °C) 5 1.35-1.45 (9H, m), 1.92-2.01 (1H, m), 2.09-2.41 (7H, m), 2.82-3.32 (5H, m), 3.62-3.86 (6H, m), 4.67-5.09 (1H, m), 6.18 (1H, s), 12.50 (1H, s).
[0705] Intermediate 22
[0706] tert-Butyl (3A.4M-3-hydroxy-4-methoxy-4-(l'.3'.5'-trimethyl-l'J / .2J / -r3.4'-bipyrazol]-5-yl)piperidine-l-carboxylate
[0707] and
[0708] Intermediate 23
[0709] tert-Butyl (3.4A)-3-hydroxy-4-methoxy-4-(l'.3'.5'-trimethyl-l'J / .2J / -r3.4'-bipyrazol]-5-yl)piperidine-l-carboxylate
[0710] The enantiomers of rac-tert-butyl (3A,45)-3-hydroxy-4-methoxy-4-(l',3',5'-trimethyl-UT, 17 / -[3,4'-bipyrazol]-5-yl)piperidine-l-carboxylate Intermediate 21 (6.15 g, 15.17 mmol) were separated by chiral preparative SFC on a Chiralpak IA column (5 pm, 250^50 mm ID), using EtOH / DEA (100 / 20 mM) in CO2 as mobile phase (isocratic: 25%). The first eluted compound was collected to yield the title compound Intermediate 22 (2.8 g, 46%, 99.6 ee). MS (ESI) m / z [M+H]+406.5.
[0711] [a]20D-16.8 (c 1.1, MeCN). The second eluted compound was collected to yield the title compound Intermediate 23 (2.8 g, 46%, 95.8 ee). MS (ESI) m / z [M+H]+406.3. [a]20D+14.9 (c 1.1, MeCN).
[0712] Intermediate 24
[0713] (3AAM-4-Methoxy-4-(l' 'A'-trimethyl-17L2J / -r3.4'-bipyrazol]-5-yl)piperidin-3-olZc / V-Butyl (3 / ,4, S')-3-hydroxy-4-methoxy-4-(r,3',5'-trimethyl-T7 / ,27 / -[3,4'-bipyrazol]-5-yl)piperidine-l-carboxylate Intermediate 22 (2.8 g, 6.91 mmol) was dissolved in EtOAc (25 mL). 6 M HC1 in IPA (11.51 mL, 69.05 mmol) was added dropwise, and the reaction mixture was stirred at 50 °C for 3 h. The mixture was concentrated under reduced pressure to give the HCl-salt of the title compound (2.483 g, 95%). MS (ESI) m / z [M+H]+306.4. *HNMR (500 MHz, DMSO-6, 25 °C) 52.2-2.31 (4H, m), 2.32-2.42 (4H, m), 2.87-2.99 (4H, m), 3.02-3.14 (2H, m), 3.2-3.29 (1H, m), 3.73 (3H, s), 4.05 (1H, s), 6.31 (1H, s), 8.40 (1H, d), 9.44 (1H, d).
[0714] Intermediate 25
[0715] (3A,4M-4-Methoxy-l-((4-methylquinazolin-2-yl)methyl)-4-(l\3\5'-trimethyl- bipyrazol]-5-yl)piperidin-3-ol
[0716]
[0717] A mixture of (3A,45)-4-methoxy-4-(l',3',5'-trimethyl-17 / ,2J / -[3,4'-bipyrazol]-5-yl)piperi din-3 -ol, HCl-salt Intermediate 24 (2.483 g, 6.56 mmol), 2-(chloromethyl)-4-methylquinazoline (1.227 g, 6.30 mmol) and K2CO3 (7.26 g, 52.51 mmol) in MeCN (48 mL) were stirred at 60 °C for 24 h. After cooling to rt, solids were filtered off and washed with MeCN. The filtrate was concentrated under reduced pressure and the residue was purified by preparative SFC, PrepMethod DD, (isocratic 30%), to give the title compound (1.50 g, 50%, 97.8%
[0718] 20
[0719] ee) as white solid after lyophilization, [a] o -17.6 (c 1.00, MeCN). H NMR (500 MHz, Methanol-t / 4) 82.05 - 2.37 (7H, m), 2.37 - 2.62 (2H, m), 2.64 - 2.94 (2H, m), 3.00 (3H, s), 3.01-3.11 (4H, s), 3.75 (3H, s), 3.83 - 4.03 (3H, m), 6.30 (1H, s), 7.71 - 7.77 (1H, m), 7.97 - 8.02 (2H, m), 8.30 (1H, dt).13C NMR (126 MHz, CDCl3) 6 169.04, 161.61, 149.65, 145.46, 137.35, 134.01, 128.77, 127.61, 125.09, 123.08, 110.06, 103.31, 75.07, 70.39, 63.91, 55.06, 55.04, 50.45, 49.20, 36.00, 28.22, 21.74, 13.13, 10.77. HRMS (ESI) m / z [M+H]+calcd for C25H32N7O2:
[0720] 462.2612, found: 462.2616
[0721] Intermediate 26
[0722] terLButyl 4-(3-oxo-3-(pyri din-3 -yllpropanoyllpiperi dine- 1 -carboxylateCDI (3.89 g, 24.0 mmol) was added to l-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (5.00 g, 21.8 mmol) in THF (42 mL) and the mixture was stirred at rt for 1 h. In a separate flask, 1 M LiHMDS in toluene (43.6 mL, 43.6 mmol) was added dropwise to a solution of 3 -acetylpyridine (4.79 mL, 43.6 mmol) in THF (42 mL) at -78 °C and stirred for 30 min. The solution containing CDI-activated carboxylic acid was added dropwise to the acetylpyridine solution and the reaction mixture was allowed to warm to rt. The reaction mixture was diluted with EtOAc and washed sequentially with 10% citric acid (aq), NaHCO3(aq) and brine. The organic layer was dried over Na2SO4, filtered and concentrated. The crude residue was purified by straight phase flash chromatography on silica (gradient 35-65% EtOAc in heptane) to give the title compound (5.91 g). The product contained 3 -acetylpyridine. MS (ESI) m / z [M+H]+333.3.
[0723] Intermediate 27
[0724] tert-Butyl 4-(5-(pyridin-3-yl)-lrt-pyrazol-3-yl)piperidine-l-carboxylate
[0725] 35% Hydrazine hydrate (aq, 2.63 mL, 29.0 mmol)) was added to a solution of tertbutyl 4-(3 -oxo-3 -(pyri din-3 -yl)propanoyl)piperi dine- 1 -carboxylate Intermediate 26 (8.12 g, 22.0 mmol) in EtOH (85 mL). The reaction mixture was stirred at rt for 3 h. The mixture was diluted with EtOAc and water. The organic layer was separated and washed with brine, dried over Na2SO4, filtered and concentrated. 1.2 g of the crude product was purified by preparative HPLC, PrepMethod F, (gradient:25-85%), and the remainder of the crude material was purified by washing with EtOAc. The two batches were combined to grant the title compound (5.4 g, 70%) as a white solid. MS (ESI) m / z [M+H]+329.3.
[0726] Intermediate 28
[0727] 3-(3-(Piperidin-4-yl)-lrt-pyrazol-5-yl)pyridine
[0728] TFA (5 mL, 64.9 mmol) was added to a solution of tert-butyl 4-(5-(pyridin-3-yl)- 1H-pyrazol-3-yl)piperidine-1-carboxylate Intermediate 27 (1g, 3.04 mmol) in DCM (30 mL) and the reaction mixture was stirred at 20 °C for 2 h. The solvent was removed under reduced pressure. The crude product was purified by reversed phase flash chromatography on a Cl 8 column (gradient: 9-90% MeCN in water),to give the TFA salt of the title compound (0.70 g) as a pale yellow oil. MS (ESI) m / z [M+H]+229.1.
[0729] Intermediate 29
[0730] 4-Methyl-2-((4-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)piperidin-1-yl)methyl)quinazoline
[0731] K2CO3 (363 mg, 2.63 mmol), KI (36.4 mg, 0.22 mmol) and 2-(chloromethyl)-4-methylquinazoline (422 mg, 2.19 mmol) were added to a solution of 3-(3-(piperidin-4-yl)-U / -pyrazol-5-yl)pyridine Intermediate 28 (500 mg, 2.19 mmol) in DMSO (15 mL) and the reaction mixture was stirred at rt for 16 h. The crude product was purified by preparative HPLC, PrepMethod E, (gradient 22-35%), to grant the title compound (693 mg, 82%) as a white solid.1H NMR (400 MHz, DMSO-d6) 8 1.71 (2H, m), 1.90 (2H, m), 2.29 (2H, t), 2.68 (1H, m), 2.93 (3H, s), 3.04 (2H, m), 3.82 (2H, s), 6.61 (1H, s), 7.41 (1H, m), 7.72 (1H, m), 7.94 - 8.00 (2H, m), 8.11 (1H, m), 8.27 (1H, m), 8.47 (1H, m), 8.98 (1H, m), 12.79 (1H, s). HRMS (ESI) m / z [M+H]+calcd for C23H25N6: 385.2136, found: 385.2146.
[0732] Intermediate 30
[0733] tert-Butyl 4-(3-oxo-3-(E3.5-trimethyl-lJ / -pyrazol-4-yl)propanoyl)piperidine-l-carb oxy late
[0734] 1-(1,3,5-Trimethyl-1H-pyrazol-4-yl)ethan-1-one (21.6 g, 0.14 mol) was dissolved in THF (600 mL) under an atmosphere of Ar (g). The turbid solution was cooled in an ice bath to 3 °C. 1 M KHMDS in THF (250 mL, 0.25 mol) and 1 M NaHMDS in THF (34 mL, 0.03 mol) were added dropwise, within 15 min, maintaining the temperature below 5 °C. The reaction mixture was stirred for 30 min and then 1-(tert-butyl) 4-methyl piperidine-1,4-dicarboxylate (69.1 g, 0.28 mol) was added in 5 portions over 10 min. The reaction mixture was heated to 60 °C for 16 h. The mixture was cooled to rt and brine (200 mL) was added. The organic solvent was removed in vacuo and the residue was extracted with EtOAc (4x150 mL). The combined organic layers were dried over Na2SO4, filtered and then concentrated in vacuo. The crude residue was dissolved in MeOH (200 mL). A solution of LiOH hydrate (6.30 g, 0.15 mol) in water (200 mL) was added, andthe reaction mixture was rapidly stirred for 2 h at rt. The formed precipitate was isolated by filtration. The filtrate was concentrated under reduced pressure to approximately half volume, and a second crop of precipitate was isolated by filtration after standing for 2 h. The solids were combined, washed with a small amount of water, and dried in vacuo to afford (39.02 g, 76%) of colorless solid. MS (ESI) m / z [M+H]+364.4.
[0735] Intermediate 31
[0736] tert-Butyl 4- 4'-bipyrazol]-5-yl)piperidine-l-
[0737]
[0738] carb oxy late
[0739] / c / V-Butyl 4-(3 -oxo-3 -(1,3, 5 -trimethyl -17 / -pyrazol-4-yl)propanoyl)piperi dine-1-carboxylate Intermediate 30 (39.0 g, 107.30 mmol) was suspended in 99.5% EtOH (350 mL) and 64% hydrazine hydrate (aq, 16.31 mL, 215 mmol) was added. The reaction mixture was stirred at rt for 16 h followed by heating to 70 °C for 20 h. The mixture was concentrated in vacuo followed by the addition of DMF (100 mL). More 64% hydrazine hydrate (aq, 8.15 mL, 168.01 mmol) was added and the mixture was heated for 18 h to 70 °C. H3PO4 (2.372 mL, 36 mmol) was added and stirring was continued at 70 °C for 16 h. The mixture was concentrated in vacuo. The residue was taken up in EtOAc (350 mL), filtered, and the filtrate was washed with brine (x4), dried over Na2SO4, filtered and concentrated in vacuo. The residue was stirred for 12 h in a mixture of EtOAc (40mL) and heptane (160 mL). The solid was isolated by filtration and dried in vacuo to yield the title compound (30.26 g, 78%) as a colorless solid. 'H NMR (500 MHz, DMSO-6) 1.38 - 1.42 (9H, m), 1.49 (2H, qd), 1.86 - 1.92 (2H, m), 2.15 -2.2 (3H, m), 2.30 (3H, s), 2.81 (3H, bs), 3.66 (3H, s), 4.00 (2H, d), 6.06 (1H, s), 12.2 - 12.49 (1H, m). MS (ESI) m / z [M+H]+360.4.
[0740] Intermediate 32
[0741] l'.3'.5'-Trimethyl-5-(piperidin-4-yl)-l'J / .2J / -3.4'-bipyrazole
[0742] / c / V-Butyl 4-(l',3',5'-trimethyl-l'J / ,2J / -[3,4'-bipyrazol]-5-yl)piperidine-l-carboxylate Intermediate 31 (30.25 g, 84.15 mmol) was dissolved in a mixture of water (50 mL) and 37% HC1 (aq, 50 mL) and the reaction mixture was stirred for20 min. The mixture was concentrated in vacuo and dried overnight under vacuum. IPA (120 mL) was added to the solids and the mixture was stirred for 6 h. Solid precipitate formed was isolated by filtration and washed with small amounts of IPA, IPA / MTBE (1:1) and MTBE. The precipitate was dried under vacuum to give the HCl-salt of the title compound (26.733 g, 96%) as colourless solid1H NMR (500 MHz, D2O, 25°C) 5 1.88-2.00 (2H, m), 2.24-2.30 (2H, m), 2.35 (6H, d), 3.11-3.26 (3H, m), 3.52 (2H, dt), 3.88 (3H, s), 6.49-6.53 (1H, m). MS (ESI) m / z [M+H]+260.4.
[0743] Intermediate 33
[0744] 4-Methyl-2-((4-(l\3\5'-trimethyl-rJ / ,2J / -r3,4'-bipyrazol1-5-yl)piperidin-l-yl)methyl)quinazoline
[0745] r,3',5'-Trimethyl-5-(piperidin-4-yl)-17 / ,2J / -3,4'-bipyrazole, HC1 Intermediate 32 (26.73 g, 80.44 mmol) was added to a turbid solution of 2-(chloromethyl)-4-methylquinazoline (13.887 g, 72.09 mmol) in MeCN (500 mL), followed by addition of K2CO3 (44.5 g, 321.7 mmol) and the reaction mixture was heated to 60 °C for 1 d. Further K2CO3 (16 g, 116 mmol) was added, and heating was continued for 20 h. Precipitated solids were removed by filtration and set aside. The filtrate was concentrated in vacuo to give a crude foam. The precipitated solids were diluted with water (300 mL) and extracted with DCM (x2). The combined organic layers were washed with a solution of K2CO3 (0.5 g, 2.61 mmol) in brine, dried over Na2SO4 and concentrated to give a crude foam. The two crude batches were combined and purified by preparative SFC, PrepMethod V, (isocratic: 7%), to grant the title compound (21 g, 70%) as a tan foam.1H NMR (500 MHz, DMSO-t / e) 1.63 - 1.73 (2H, m), 1.84 - 1.9 (2H, m), 2.18 (3H, s), 2.23 - 2.38 (5H, m), 2.57 - 2.67 (1H, m), 2.93 (3H, s), 3 - 3.05 (2H, m), 3.66 (3H, s), 3.80 (2H, s), 6.05 (1H, s), 7.68 - 7.75 (1H, m), 7.96 - 7.98 (2H, m), 8.25 - 8.29 (1H, m), 12.13 - 12.51 (1H, m). HRMS (ESI) m / z [M+H]+calcd for C24H30N7: 416.2558, found: 416.2572.Example 1
[0746] 2-((4-(5'-Methoxy-r-methyl-1 f 2Z / -r3,4'-bipyrazol]-5-yl)piperidin-l-yl)methyl)- orm A
[0747]
[0748] 2-((4-(5'-Methoxy-r-methyl-177,2J7-[3,4'-bipyrazol]-5-yl)piperidin-l-yl)methyl)-4,7-dimethylpyrido[2,3-t ]pyrimidine Intermediate 9 (87 mg, 0.20 mmol) and anhydrous orotic acid (28.1 mg, 18 mmol) were dissolved in MeOH and stirred at rt for 10 min. A small turbidity was filtered off and the filtrate was concentrated in vacuo. The residue was stirred in IPA (6 mL) and then a solid was filtered off. The mother liquid was concentrated in vacuo at rt to half volume, and then left standing at rt overnight. The precipitate was isolated using decantation, washed with IPA, and dried in vacuo to give the title compound (10 mg, 8.5%).
[0749] The solid residue was found to be crystalline by XRPD (form A) and a typical diffractogram by standard Bragg-Brentano powder X-ray diffraction is displayed in Figure 1. Characteristic peak positions are listed below in Table 2.
[0750] Table 2. Five peaks characteristic for Example 1, form A
[0751] °2-theta Relative intensity
[0752] 4.8 vs
[0753] 8.5 w
[0754] 9.6 s
[0755] 14.4 s
[0756] 17.0 m
[0757] 19.5 m
[0758] 24.3 m
[0759] 24.8 s
[0760] 26.3 w
[0761] 27.3 sExample 2
[0762] 2-((4-(5'-Methoxy-r-methyl-1 L2Z / -r3,4'-bipyrazol]-5-yl)piperidin-l-yl)methyl)- orm B
[0763]
[0764] ,, azol]-5-yl)piperidin-l-yl)methyl)- 4,7-dimethylpyrido[2,3- ]pyrimidine Intermediate 9 (39.9 mg, 0.09 mmol) was dissolved in a mixture of MeCN (2 mL) and MeOH (0.2 mL). The mixture was heated to ~35°C until a clear solution was obtained. Anhydrous orotic acid (14.4 mg, 0.09 mmol) was added followed by water (~0.8 mL) until a clear solution was obtained. MeCN (-6 mL) was added dropwise, and the mixture was left standing for 10 min. The mixture was concentrated in vacuo and the residue was redissolved in MeOH (2 mL). MeCN (3 mL) was added, and the mixture was left standing at rt overnight. 1.3 mL of the solution was transferred into a vial, and the vial was left standing in a vial containing DIPE for 3 days. The precipitate was collected by filtration and dried in vacuo to give the title compound (12 mg, 22.1%) as a colourless solid.
[0765] The solid residue was found to be crystalline by XRPD (form B) and a typical diffractogram by standard Bragg-Brentano powder X-ray diffraction is displayed in Figure 2. Characteristic peak positions are listed below in Table 3.
[0766] Table 3. Five peaks characteristic for Example 2, form B
[0767] °2-theta Relative intensity
[0768] 15.3 s
[0769] 18.1 s
[0770] 20.0 vs
[0771] 20.4 m
[0772] 21.0 m
[0773] 22.2 w
[0774] 23.6 m24.3 s
[0775] 26.5 m
[0776] 27.3 vs
[0777] Example 3
[0778] 2-((4-(l\5'-Dimethyl-17L2. H-r3N'-bipyrazol]-5-yl)-4-methoxypiperidin-l-yl)methyl)-4-methylquinazoline orotate
[0779]
[0780] 2-((4-(1',5'-Dimethyl-1'H,2H-[3,4'-bipyrazol]-5-yl)-4-methoxypiperidin-l-yl)methyl)-4-methylquinazoline Intermediate 14 (40 mg, 0.09 mmol) and anhydrous orotic acid (14.4 mg, 0.09 mmol) were stirred in a mixture of MeCN (1 mL) and MeOH (0.1 mL) at rt for 15 min. Water (~0.8 mL) was added dropwise to the suspension until a clear yellow solution was obtained. MeCN (-3 mL) was added dropwise, and the solution was allowed to stand for 3 h. The precipitate was collected by filtration and washed with a mixture of MeCN: MeOH (2 mL, 10:1) and dried in vacuo for 2 h to give the title compound (17 mg, 31%) as a colorless solid.
[0781] The solid residue was found to be crystalline by XRPD and a typical diffractogram by standard Bragg-Brentano powder X-ray diffraction is displayed in Figure 3. Characteristic peak positions are listed below in Table 4.
[0782] Table 4. Five peaks characteristic for Example 3
[0783] °2-theta Relative intensity
[0784] 7.0 m
[0785] 10.3 w
[0786] 10.7 w
[0787] 12.9 vs
[0788] 14.0 w14.9 s
[0789] 15.2 m
[0790] 16.2 w
[0791] 20.7 w
[0792] 25.2 m
[0793] Example 4
[0794] (3A,4M-4-Methoxy-l-((4-methylquinazolin-2-yl)methyl)-4-(l\3\5'-trimethyl- 17L2J / -13,4'-bipyrazol1-5-yl)piperidin-3-ol orotate
[0795]
[0796] (37?,4S)-4-Methoxy-l-((4-methylquinazolin-2-yl)methyl)-4-(r,3',5'-trimethyl-17 / ,2J / -[3,4'-bipyrazol]-5-yl)piperidin-3-ol Intermediate 25 (2 g, 4.3 mmol) was suspended in MeCN (6 mL) and stirred until a clear solution was obtained.
[0797] Anhydrous orotic acid (0.68 g, 4.3 mmol) was added to the vial followed by addition of MeOH (2 mL) and the resultant suspension stirred for 24 hours.
[0798] Additional MeOH (1 mL) was added after 24 hours. The suspension was filtered and dried under vacuum at 40 °C for 24 hours to give the title compound (2.35 g, 87.8%).
[0799] The solid residue was found to be crystalline by XRPD. A typical diffractogram by standard Bragg-Brentano powder X-ray diffraction is displayed in Figure 4. Characteristic peak positions are listed below in Table 5.
[0800] Table 5. Five peaks characteristic for Example 4, Bragg-Brentano powder X-ray diffraction
[0801] °2-theta Relative intensity
[0802] 11.9 s
[0803] 13.1 s14.2 s
[0804] 15.6 s
[0805] 16.4 m
[0806] 16.7 m
[0807] 23.1 vs
[0808] 23.7 m
[0809] 24.4 s
[0810] 25.5 s
[0811] A typical diffractogram by capillary transmission powder X-ray diffraction is displayed in Figure 5. Characteristic peak positions are listed below in Table 6.
[0812] Table 6. Five peaks characteristic for Example 4, capillary transmission powder X-ray diffraction
[0813] °2-theta Relative intensity
[0814] 4.9 m
[0815] 9.0 m
[0816] 11.9 m
[0817] 13.2 s
[0818] 14.2 s
[0819] 15.7 vs
[0820] 16.8 m
[0821] 23.2 s
[0822] 23.7 m
[0823] 24.5 m
[0824] Example 5
[0825] 4-Methyl-2-((4-(5-(pyridin-3-yl)-lZ / -pyrazol-3-yl)piperidin-l-yl (methyl (quinazoline orotate
[0826]
[0827] 4-Methyl-2-((4-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)piperidin-1-yl)methyl)quinazoline Intermediate 29 (52 mg, 0.14 mmol) and anhydrous orotic acid (21 mg, 0.13 mmol) were stirred in a mixture of MeCN (3 mL) and MeOH (2 mL). After 15 min a small amount of insoluble was removed by filtration and the filtrate was concentrated in vacuo to give a colourless solid. The solids were gently stirred for a day in a mixture of MeCN: MeOH (2.5 mL, 9:1). The mixture was left standing for an additional 16 h. The solids were collected by filtration, washed with a small amount of MeCN, and dried in vacuo for 30 min to give the title compound (12 mg, 16.4%).
[0828] The solid residue was found to be crystalline by XRPD. A typical diffractogram by standard Bragg-Brentano powder X-ray diffraction is displayed in Figure 6.
[0829] Characteristic peak positions are listed below in Table 7.
[0830] Table 7. Five peaks characteristic for Example 5
[0831] °2-theta Relative intensity
[0832] 5.1 s
[0833] 10.2 m
[0834] 11.2 m
[0835] 15.1 vs
[0836] 16.0 s
[0837] 18.4 s
[0838] 21.0 m
[0839] 24.3 s
[0840] 24.5 s
[0841] 26.0 s
[0842] Example 64-Methyl-2-((4-(1',3',5'-trimethyl-1'H,2H-[3,4'-bipyrazol]-5-yl)piperidin-1-
[0843]
[0844] 4-Methyl-2-((4-(1',3',5'-trimethyl-1'H,2H-[3,4'-bipyrazol]-5-yl)piperidin-1-yl)methyl)quinazoline Intermediate 33 (200 mg, 0.48 mmol) and anhydrous orotic acid (71 mg, 0.45 mmol) were stirred in a mixture of MeCN (4 mL) and MeOH (0.4 mL) at rt for 30 min. 1.1 mL of the suspension was separated out and water (~1 mL) was added dropwise until a clear solution was obtained. MeCN (6 mL) was added, and the solution was left standing at rt for 3 h. The precipitate formed was filtered off, washed with a mixture of MeCN: MeOH (~2 mL, 10: 1) and dried in vacuo for 2 h to give the title compound (61 mg, 22%) as a colourless solid.
[0845] The solid residue was found to be crystalline by XRPD. A typical diffractogram by standard Bragg-Brentano powder X-ray diffraction is displayed in Figure 7.
[0846] Characteristic peak positions are listed below in Table 8.
[0847] Table 8. Five peaks characteristic for Example 6
[0848] °2-theta Relative intensity
[0849] 5.0 vs
[0850] 10.0 w
[0851] 10.3 m
[0852] 15.1 w
[0853] 16.6 vw
[0854] 18.7 w
[0855] 19.8 vw
[0856] 24.6 vw
[0857] 25.3 vw
[0858] 27.6 vw
Claims
1. CLAIMS1. An orotate crystalline addition salt of a compound of Formula (I)R1 is selected from a 8-, 9- or 10-membered heteroaryl substituted by R8, R10 and 0, 1 or 2 substituents independently selected from R9;R2 is independently selected from H, CH3, CH2F, CHF2 and CF3;R3is selected from a 5- or 6-membered heteroaryl substituted by R10, 0, 1 or 2 substituents independently selected from RH, 0, 1 or 2 substituents independently selected from R12 and 0 or 1 substituents independently selected from R13 or a 8-, 9- or 10-membered heteroaryl substituted by R10, 0, 1 or 2 substituents independently selected from RH, 0, 1 or 2 substituents independently selected from R12 and 0 or 1 substituents independently selected from RIS;R3is selected from H, OH, C|.3 alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl;R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3;R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;R3is selected from H, F, Cl, CN, C^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC^alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH(CH3)2, oxetane, cyPr or cyBu;R8 is independently selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3, -CH(CH3)2, cyPr, cyBu, CN, F or Cl;R9 is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -O(oxetane) substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3, -CH(CH3)2, CN, F or Cl;R10 is selected from H, CH3, CH2F, CHF2, CF3, CH2CH3, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3;R11is independently selected from C1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-2alkyl optionally substituted by 1, 2, 3, 4 or 5 F, CH2OCH3, CH2cyPr, cyPr substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3 or cyBu substituted by 0 or 1 substituent selected from F, CH3, CH2F, CHF2 or CF3;R12 is independently selected from CH3, OH, OCH3, CH2F, CHF2, CF3, CH2CH3, CH2OCH3, -CH(CH3)2, CN, Cl, NHCH3 or CH2OH;R13 is selected from a 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3, or -O(6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently selected from O, S or N) wherein said 6-membered heterocycloalkyl ring is optionally substituted by 0, 1 or 2 substituents independently selected from F, OH, CH3, CH2F, CHF2, CF3, CH2CH3, OCH3, OCH2F, OCHF2, OCF3 or (CO)CH3; andm is independently 0, 1 or 2.
2. An orotate crystalline addition salt according to claim 1 wherein R1 is selected from5 R3 is selected from117n is 0, 1 or 2;p is 0, 1 or 2; andq is 0, 1 or 2.
4. An orotate crystalline addition salt according to any one of claims 1 to 3 whereinR4is selected from OH, OCH3, OCH2F, OCHF2, OCF3, -CH2OH, CN, F.
5. An orotate crystalline addition salt according to claim 4 wherein5 6. An orotate crystalline addition salt according to claim 4 wherein7. An orotate crystalline addition salt according to claim 1 whereinR2is H;R3 is selected fromR4 is selected from OH, C1-3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, OC1-3alkyl optionally substituted by 1, 2, 3, 4 or 5 F, -CH2OH, -CH2OCH3, CN, F, Cl;R is independently selected from H, F, OH, OCH3, OCH2F, OCHF2, OCF3, CH3, CH2F, CHF2or CF3;R is independently selected from CH3, CH2F, CHF2, CF3, CH2CH3or F;R7is selected from H, F, CH3or CN;R8is independently selected from H, CH3or OCH3;R9is independently selected from CH3, OCH3, CN, F or Cl;R10is selected from H or CH3;R11is independently selected from CH3 or OCH3;R12is independently selected from CH3, OCH3, CN or Cl;m is independently 0, 1 or 2;n is 0, 1 or 2;p is 0, 1 or 2;q is 0, 1 or 2.
8. An orotate crystalline addition salt according to claim 1 selected from2-((4-(5'-Methoxy-1'-methyl-1'H,2H-[3,4'-bipyrazol]-5-yl)piperidin-1-yl)methyl)-4,7-dimethylpyrido[2,3-d]pyrimidine orotate, Form A;2-((4-(5'-Methoxy-1'-methyl-1'H,2H-[3,4'-bipyrazol]-5-yl)piperidin-1-yl)methyl)-4,7-dimethylpyrido[2,3-d]pyrimidine orotate, Form B;2-((4-(1',5'-Dimethyl-1'H,2H-[3,4'-bipyrazol]-5-yl)-4-methoxypiperidin-1-yl)methyl)-4-methylquinazoline orotate;(3R,4S)-4-Methoxy-1-((4-methylquinazolin-2-yl)methyl)-4-(1',3',5'-trimethyl-1'H,2H-[3,4'-bipyrazol]-5-yl)piperidin-3-ol orotate;4-Methyl-2-((4-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)piperidin-l-yl)methyl)quinazoline orotate;4-Methyl-2-((4-(1',3',5'-trimethyl-1'H,2H-[3,4'-bipyrazol]-5-yl)piperidin-1-yl)methyl)quinazoline orotate.
9. An orotate crystalline addition salt according to any one of claims 1 to 8, for use as a medicament.
10. A pharmaceutical composition comprising an orotate crystalline addition salt according to any one of claims 1 to 8, optionally in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
11. A method of treating, or reducing the risk of, diseases or conditions in which inhibition of the enzyme NNMT is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of an orotate crystalline addition salt according to any one of Claims 1 to 8.
12. The method according to claim 11, wherein said disease or condition is chronic kidney disease (CKD).
13. The method according to claim 11, wherein said disease or condition is acute kidney injury (AKI).
14. The method according to claim 11, wherein said disease or condition is diabetic kidney disease (DKD).
15. An orotate crystalline addition salt according to any one of claims 1 to 8 for use as a medicament.
16. An orotate crystalline addition salt according to any one of claims 1 to 8 for use in the treatment of chronic kidney disease (CKD).
17. An orotate crystalline addition salt according to any one of claims 1 to 8 for use in the treatment of acute kidney injury (AKI).
18. An orotate crystalline addition salt according to any one of claims 1 to 8 for use in the treatment of diabetic kidney disease (DKD).
19. The use of an orotate crystalline addition salt according to any one of claims 1 to 8 in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme NNMT is beneficial.
20. The use according to claim 19, wherein said disease or condition is chronic kidney disease (CKD).
21. The use according to claim 19, wherein said disease or condition is acute kidney injury (AKI).
22. The use according to claim 19, wherein said disease or condition is diabetic kidney disease (DKD).
